UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUATERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal ~~nine~~three months ended ~~September~~March 3031, ~~2021~~2022

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from: _____________to______________

333-222083

(Commission File Number)

Regnum Corp.

(Exact name of registrant as specified in its charter)

Nevada

82-0832447

(State or Other Jurisdiction

of Incorporation or Organization)

(I.R.S. Employer

Identification No.)

600 ~~3rd~~Third ~~Ave Floor 19New York~~Avenue, NY19th ~~10016~~Floor

New York, NY 10016

(Address of Principal Executive Office) (Zip Code)

(~~917~~877) ~~647~~313-~~1498~~2232

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None.

Securities registered pursuant to Section 12(g) of the Act: None.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☒ No ☐

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” ~~and~~ “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated ~~filer~~Filer ☒ Smaller reporting company ☒ Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~November~~May 2220, ~~2021~~2022, there were 22,950,000 shares of common stock issued and outstanding.

DOCUMENTS INCORPORATED BY REFERENCE: None.

None.

	TABLE OF CONTENTS

		Pages

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements	3
	Condensed Balance Sheets as of March 31, 2022 (Unaudited) and December 31, 2021 (Audited)	3
	Unaudited Condensed Statements of Operations for the Three Months ended March 31, 2022 and 2021	4
	Unaudited Condensed Statements of Stockholders’ Deficit as of March 31, 2022, and 2021	5
	Unaudited Condensed Statements of Cash Flows for the Three Months March 31, 2022 and 2021	6
	Notes to Condensed Financial Statements (Unaudited)	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	16
Item 4.	Controls and Procedures	16

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	18
Item 1A.	Risk Factors	18
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18
Item 3.	Defaults Upon Senior Securities	18
Item 4.	Mine Safety Disclosures	18
Item 5.	Other Information	18
Item 6.	Exhibits	19

SIGNATURES		20

	TABLE OF CONTENTS
		Pages
PART I. FINANCIAL INFORMATION		3
Item 1.	Financial Statements	3
	Condensed Balance Sheets as of September 30, 2021 (unaudited) and December 31, 2020	3
	Condensed Statements of Operations for the three and nine month periods ended September 30, 2021 and 2020 (unaudited)	4
	Condensed Statements of Stockholders’ Equity as of September 30, 2021, and 2020 (unaudited)	5
	Condensed Statements of Cash Flows for the nine months ended September 30 2021 and 2020 (unaudited)	6
	Notes to Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	11
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	13
Item 4.	Controls and Procedures	14
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	15
Item 1A.	Risk Factors	15
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	22
Item 3.	Defaults Upon Senior Securities	22
Item 4.	Mine Safety Disclosures	22
Item 5.	Other Information	22
Item 6.	Exhibits	29
SIGNATURES		28

Table of Contents

PART I. FINANCIAL ~~INFORMATIONITEM~~INFORMATION ITEM 1. FINANCIAL STATEMENTS. REGNUM CORP. ~~Balance~~CONDENSED ~~Sheet~~BALANCE SHEETS

	September 30,			December 31,
	March 31,			December 31,
	2021			2020
	2022			2021
	(Unaudited)			(Audited)
ASSETS
CURRENT ASSETS
Cash	$	-1,400,107		$	-1,488,419
Accounts receivable		-			4,500
Prepaid Assets		500			500
Prepaid Assets		4,000			-
Total Current Assets		1,400,607			1488,919
Total Current Assets		4,000			4,500
TOTAL ASSETS	$	1,400,607		$	1,488,919
TOTAL ASSETS	$	4,000		$	4,500
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Accounts payable	$	~~13,018~~-		$	52,~~523~~000
Accrued Expenses		914,~~750~~720			-16,284
Accrued taxes payable		800			800
Accounts payable - related party		95520,~~397~~937			48339,~~570~~179
Total Current Liabilities		118,965			54,893
Promissory Note		1,521,575			1,510,479
TOTAL LIABILITIES		118,965			54,893
Total Current Liabilities		2,058,032			1,868,742
TOTAL LIABILITIES	$	2,058,032		$	1,868,742
STOCKHOLDERS’ EQUITY
Common stock: $0.001 par value, 80,000,000
Common stock: $0.001 par value, 80,000,000 shares authorized, 22,950,000 Shares issued and outstanding		22,950			22,950
shares authorized, 22,950,000 and 23,950,000
Additional paid-in capital		18,550			18,550
Shares issued and outstanding, respectively		22,950			23,950
Retained earnings		(698,925	)		(421,323	)
Additional paid-in capital		18,550			77,150
Total Stockholders’ Equity		(657,425	)		(379,823	)
Retained earnings		(156,465	)		(151,493	)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	1,400,607		$	1,488,919
Total Stockholders’ Equity		(114,965	)		(50,393	)
TOTAL LIABILITIES AND
STOCKHOLDERS’ EQUITY	$	4,000		$	4,500

The accompanying notes are an integral part of these financial statements.

Table of Contents

REGNUM CORP. ~~Statements~~CONDENSED ofSTATEMENTS ~~Operations~~OF OPERATIONS (UNAUDITED)

	For the Three Months Ended						~~For the Nine Months Ended~~
	September 30,						September 30,
	March 31,
	2021			2020			2021			2020
	2022			2021
REVENUES	$	-		$	~~2,250~~-		$	-		$	~~6,750~~
COST OF SALES		-			~~2,228~~-			-			~~2,228~~
GROSS PROFIT		-			22-			-			~~4,522~~
OPERATING EXPENSES
Amortization of Intangibles		-			1,500			-			3,757
Legal and professional fees		95,097			2,860
Legal and professional fees		64,121			6,904			67,180			53,249
General and administrative		182,505			480
General and administrative		34,026			1,340			46,815			64,472
Total Operating Expenses		277,602			3,340
Total Operating Expenses		98,147			9,744			113,995			121,478
INCOME (LOSS) FROM OPERATIONS		(277,602	)		(3,340	)
INCOME (LOSS) FROM OPERATIONS		(98,147	)		(9,722	)		(113,995	)		(116,956	)
OTHER INCOME		-			-
OTHER INCOME		-			-			109,023			-
INCOME (LOSS) BEFORE TAXES		(277,602	)		(3,340	)
INCOME (LOSS) BEFORE TAXES		(98,147	)		(9,722	)		(4,972	)		(116,956	)
INCOME TAX EXPENSE		-			-
INCOME TAX EXPENSE		-			-			-			-
NET INCOME (LOSS)	$	(277,602	)	$	(3,340	)
NET INCOME (LOSS)	$	(98,147	)	$	(9,722	)	$	(4,972	)	$	(116,956	)
BASIC AND DILUTED INCOME PER COMMON SHARE	$	(0.01	)	$	-
BASIC AND DILUTED INCOME
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING		22,950,000			23,950,000
PER COMMON SHARE	$	-		$	-		$	-		$	-
WEIGHTED AVERAGE NUMBER
OF COMMON SHARES
OUTSTANDING		22,950,000			23,950,000			23,301,648			23,634,982

The accompanying notes are an integral part of these financial statements.

Table of Contents

REGNUM CORP
REGNUM CORP.
Statements of Stockholders’ Equity (Deficit)For the nine months ended September 30, 2021 and 2020
CONDENSED STATEMENTS OF STOCKHOLDERS’ DEFICIT (UNAUDITED) FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021
										Retained
							Additional			Earnings			Total
	Common Stock						Paid-In			(Accumulated			Stockholders’
	Shares			Amount			Capital			Deficit)			Equity
Balance, December 31, 2021		22,950,000			22,950			18,550			(421,323	)		(379,823	)
Net loss for the quarter ended March 31 2022		-			-			-			(277,602	)		(277,602	)
Balance, March 31, 2022		22,950,000		$	22,950		$	18,550		$	(698,925	)	$	(657,425	)
Balance, December 31, 2020		23,950,000			23,950			77,150			(151,493	)		(50,393	)
Net loss for the quarter ended March 31 2021		-			-			-			(3,340	)		(3,340	)
Net loss for the quarter ended March 31, 2021		-			-			-			(3,340	)		(3,340	)
Balance, March 31, 2021		23,950,000		$	23,950		$	77,150		$	(154,833	)	$	(53,733	)
Balance March 31, 2021		23,950,000		$	23,950		$	77,150		$	(154,833	)	$	(53,733	)
Cancellation of common shares issued for services rendered		(1,000,000	)		(1,000	)		(58,600	)		-			(59,600	)
Net income for quarter ended June 30, 2021		-			-			-			96,515			96,515
Balance June 30, 2021		22,950,000			22,950			18,550			(58,318	)		(16,818	)
Net income for quarter ended September 30, 2021		-			-			-			(98,147	)		(98,147	)
Balance September 30, 2021		22,950,000			22,950			18,550			(156,465	)		(114,965	)
Balance, December 31, 2019		22,950,000			22,950			18,550			(33,820	)		7,680
Common shares issued for services rendered		1,000,000			1,000			58,600			-			59,600
Net loss for the quarter ended March 31, 2020		-			-			-			(67,044	)		(67,044	)
Balance March 31, 2020		23,950,000			23,950			77,150			(100,864	)		236
Net loss for the quarter ended June 30, 2020		-			-			-			(40,190	)		(40,190	)
Balance June 30, 2020		23,950,000			23,950			77,150			(141,054	)		(39,954	)
Net loss for the quarter ended September 30, 2020		-			-			-			(9,722	)		(9,722	)
Balance September 30, 2020		23,950,000			23,950			77,150			(150,776	)		(49,676	)

The accompanying notes are an integral part of these financial statements.

Table of Contents

REGNUM CORP
REGNUM CORP.
Statements of Cash Flows(Unaudited)
CONDENSED STATEMENTS OF CASH FLOWS(UNAUDITED)
	For the Nine months Ended
	For the Three Months Ended
	September 30,
	March 31,
	2021			2020
	2022			2021
OPERATING ACTIVITIES
Net income (loss)	$	(4277,~~972~~602	)	$	(~~116~~3,~~956~~340	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Common stock (cancelled) issued for services rendered		(59,600	)		59,600
Intercompany interest expense		11,096			-
Amortization of intangible assets		-			3,757
Accounts payable		(2,000	)		1,947
Changes in operating assets and liabilities:
Accrued Expenses		(1,564	)		-
Accounts receivable		4,500			(2,250	)
Accounts payable - related party		181,758			1,393
Prepaids		(4,000	)		-
Net Cash Provided By (Used In) Operating Activities		(88,312	)		-
Accounts payable		7,495			17,211
INVESTING ACTIVITIES
Accrued Expenses		9,750			-
Net Cash Provided By (Used In) Investing Activities		-			-
Accounts payable - related party		46,827			34,966
FINANCING ACTIVITIES
Net Cash Provided By (Used In) Operating Activities		-			(3,672	)
Net Cash Provided by (Used In) Financing Activities		-			-
INVESTING ACTIVITIES		-			-
NET INCREASE (DECREASE) IN CASH		(88,312	)		-
Cash paid for intangible assets		-			(3,772	)
CASH AT BEGINNING OF PERIOD		1,488,419			-
Net Cash Used In Investing Activities		-			(3,772	)
CASH AT END OF PERIOD	$	1,400,107		$	-
FINANCING ACTIVITIES		-			-
NET INCREASE (DECREASE) IN CASH		-			(7,444	)
CASH AT BEGINNING OF PERIOD		-			7,444
CASH AT END OF PERIOD	$	-		$	-
The accompanying notes are an integral part of these financial statements.

Table of Contents

REGNUM CORP.

~~Notes~~NOTES toTO ~~Financial~~CONDENSED ~~Statements~~FINANCIAL STATEMENTS

~~September~~MARCH ~~30, 2021 and December~~ 31, ~~2020~~2022

~~1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES~~(Unaudited)

~~The~~NOTE ~~accompanying unaudited consolidated interim financial statements of Regnum Corp~~1. ~~(the~~ORGANIZATION ~~“Company”~~AND orDESCRIPTION ~~“Regnum”)~~OF ~~have~~BUSINESS been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”) and should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2020, contained in the Company’s annual report, as filed with the SEC on Form 10-K on August 13, 2021 (the “Form 10-K”). The December 31, 2020 balance sheet was derived from the audited financial statements of our 2020 Form 10-K. In the opinion of management all adjustments, consisting of normal recurring adjustments necessary for a fair presentation of financial position and the results of operations for the interim periods presented, have been reflected herein.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2020 financial statements. The results of operations for the periods ended September 30, 2021 and 2020 are not necessarily indicative of the operating results for the full year.

Nature of Business

Regnum Corp. (the “Company” or “Regnum,” “we,” “us,” “our” and similar terminology) was incorporated on March 31, 2016, under the laws of the State of Nevada. The Company was originally formed for the primary business purpose of servicing the demand for premium entertainment content and becoming a depository of unpublished intellectual properties for resale with focus on achieving profitability and sustaining business growth. Following the April 7, 2021 acquisition of a super majority interest in the Company (as described in Note 7 below) by Phoenixus AG, a Swiss company (“Phoenixus”), the Company’s prior business model was abandoned.

~~Regnum~~Since ~~was~~April ~~organized~~2021, the Company’s business model is focused on ~~March~~developing 31and commercializing pharmaceutical therapeutics that treat rare and infectious diseases, ~~2016~~specifically in populations that are neglected or face adherence challenges due to inconvenient dosing or delivery system, ~~under~~tolerability, ~~the~~or ~~laws~~cost and accessibility of ~~the~~available ~~State~~therapeutic ofoptions. ~~Nevada~~Under certain license and commercial agreements with CytoDyn, Inc. ~~The~~(“CytoDyn”) ~~Company~~which ~~was~~were ~~formed~~assigned ~~for~~to athe ~~primary~~Company ~~business~~in ~~purpose~~January of2022 ~~servicing~~(see Note 4 below), the ~~increasing~~Company’s ~~demand~~primary ~~for~~asset ~~premium~~is ~~entertainment~~the ~~content~~commercial ~~and~~rights ~~becoming~~to aleronlimab ~~depository~~(also ofknown ~~unpublished~~as ~~intellectual~~“PRO ~~properties~~140”) ~~for~~in ~~resale~~all ~~with~~human ~~focus~~immunodeficiency onvirus ~~achieving~~(“HIV”) ~~profitability~~indications ~~and~~within ~~sustaining~~the ~~business~~United ~~growth~~States. ~~The~~Leronlimab ~~Company’s~~is ~~business~~the ~~model~~subject of a current Biologics License Application (“BLA”) that has been ~~based~~submitted onin ~~acquiring~~part ~~unproduced~~to the U.S. Food and ~~unpublished~~Drug ~~quality~~Administration ~~intellectual~~(“FDA”) ~~properties~~with atan aindication ~~discount~~to ~~from~~treat ~~studios,~~Multi-Drug ~~agencies~~Resistant ~~and~~HIV ~~production~~infection, ~~companies~~with the potential for ~~subsequent~~multiple ~~recycling~~additional ortherapeutic ~~production~~indications in ~~wide~~HIV. ~~variety~~As of ~~media~~the ~~with~~date of this report, the ~~intent~~FDA’s toreview ~~resell~~of ~~back~~the toBLA is ongoing. Since the ~~entertainment~~FDA ~~community~~approval ~~for~~process ais ~~profit.~~ongoing and its outcome is uncertain, we are also seeking to acquire or in-license other pharmaceutical products or product candidates, although no products have been identified to date.

InThe ~~April~~Company has submitted a Company Related Action Notification in accordance with Financial Industry Regulatory Authority (“FINRA”) Rule 6490 on October 20, 2021, ~~controlling~~in ~~shares~~connection with a proposed change of the Company’s ~~were~~name ~~acquired~~to by“Rovida ~~Phoenixus~~Therapeutics, AGInc.,” athe ~~Swiss~~redomicile ~~company~~of ~~with~~the ~~multiple~~Company ~~U.S.~~from ~~based~~Nevada ~~affiliates~~to ~~operating~~Delaware ~~within~~and a change in the ~~pharmaceutical~~Company’s ~~industry~~ticker symbol (the “~~Phoenixus~~Corporate Actions”),. atThe ~~which~~Corporate ~~point~~Actions have been approved by the ~~Company’s~~board ~~business~~of ~~plan~~directors ~~changed~~of ~~significantly~~the Company and ~~materially.~~by AsPhoenixus as the holder of ~~April~~majority ~~2021~~of the outstanding shares of common stock, $0.001 par value per share, of the Company’s ~~primary~~(the ~~business~~“Common ~~purpose~~Stock”). isThe ~~based~~Corporate onActions ~~developing~~are ~~and~~presently ~~commercializing~~under ~~therapeutics~~review ~~that~~by ~~treat~~an ~~infectious~~appeal ~~diseases~~panel of FINRA, ~~specifically~~and inno ~~rare~~assurances ~~populations~~can orbe ~~populations~~given that ~~face~~FINRA’s ~~adherence~~approval ~~challenges~~of the Corporate Actions will be granted. The Corporate Actions have been delayed due to questions by FINRA regarding Phoenixus’s former association with Martin Shkreli as disclosed in the Company’s 2021 Form 10-K.

~~Use~~Risks ofand ~~Estimates~~Uncertainties

The ~~preparation~~Company ofis ~~financial~~subject ~~statements~~to incertain ~~conformity~~risks ~~with~~common ~~accounting~~to ~~principles~~other ~~generally~~companies ~~accepted~~ in the ~~United~~biotechnology ~~States~~industry ofincluding, ~~America~~but ~~requires~~not ~~management~~limited to, ~~make~~the ~~estimates~~need ~~and~~to ~~assumptions~~raise ~~that~~additional ~~affect~~capital, ~~the~~FDA ~~reported~~review ~~amounts~~and approval of ~~assets~~the ~~and~~Company’s ~~liabilities~~products, atmarket ~~the~~acceptance ~~date~~ of the ~~financial~~Company’s ~~statements~~products, competition, healthcare reform, and ~~the~~compliance ~~reported~~with ~~amounts~~government ofregulations. ~~revenue~~There ~~and~~is ~~expenses~~uncertainty ~~during~~as ~~the~~to ~~reporting~~whether ~~period.~~the ~~Actual~~COVID-19 ~~results~~pandemic could ~~differ~~disrupt ~~from~~the ~~those~~Company’s ~~estimates~~operations or impact government oversight or the regulatory review process.

Basic Loss per Common Share

Basic loss per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are 80,000,000 common stock shares authorized at $0.001 par value and 23,950,000 and 22,950,000 shares of common stock outstanding as of December 31, 2020 and September 30, 2021, respectively. The Company had no potential dilutive shares of common stock as of September 30, 2021.

Table of Contents

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Unaudited Interim Financial Statements

The accompanying unaudited condensed interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and in accordance with the rules of the Securities and Exchange Commission (“SEC”), and should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2021, contained in the Company’s annual report, as filed with the SEC on Form 10-K on April 15, 2022 (the “Form 10-K”). The December 31, 2021 balance sheet was derived from the audited financial statements of our 2021 Form 10-K. In the opinion of management all adjustments, consisting of normal recurring adjustments necessary for a fair presentation of financial position and the results of operations for the interim periods presented, have been reflected herein.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2021 financial statements included in our 2021 Form 10-K. The interim results of operations for the three months ended March 31, 2022 are not necessarily indicative of the operating results to be expected for the year ending December 31, 2022 or for any future periods.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, certain revenues and expenses, and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Basic Income/(Loss) per Share of Common Stock

Basic income per share of Common Stock is calculated by dividing the Company’s net income/(loss) applicable to shareholders of Common Stock by the weighted average number of shares of Common Stock during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to shareholders of Common Stock by the diluted weighted average number of shares of Common Stock outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are 80,000,000 shares of Common Stock authorized, and there were 22,950,000 shares of Common Stock outstanding as of March 31, 2022 and December 31, 2021. The Company had no potential dilutive issuances of shares of Common Stock during the quarter ended as of March 31, 2022.

Table of Contents

Accounting Basis

The ~~basis~~financial isstatements ~~accounting~~are ~~principles~~prepared ~~generally accepted~~ in ~~the~~accordance ~~United~~with ~~States~~U.S. ~~of America~~GAAP. The Company has adopted a December 31 fiscal year-end.

Cash and Cash Equivalents

~~Cash~~The Company considers cash and cash equivalents to include cash in banks and financial instruments which mature within six months of the date of purchase. The carrying amount of cash and cash equivalents approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements.

Revenue Recognition

As of the date of this report, the Company is has no revenue generating operations.

~~Revenues~~If ~~from~~and when revenue generation begins, the ~~sale~~Company ofwill ~~intellectual~~perform ~~property~~the ~~are~~following ~~recognized~~five ~~when~~steps ~~persuasive~~in ~~evidence~~accordance ofwith anFASB ~~arrangement~~ASC ~~exists~~606, ~~the~~Revenue ~~intellectual~~from ~~property~~Contracts ~~has~~with ~~been~~Customers: ~~delivered~~(i) oridentify isthe ~~made~~contract ~~available~~with ~~for~~a ~~delivery~~customer, (ii) identify the ~~customer~~performance ~~can~~obligations ~~begin~~in the ~~use~~contract, of(iii) determine the ~~intellectual~~transaction ~~property~~price, (iv) allocate the ~~fee~~transaction isprice ~~fixed~~to orthe ~~determinable~~performance obligations in the contract and ~~collectability~~(v) isrecognize ~~reasonably~~revenue ~~assured~~when (or as) the entity satisfies the performance obligation. Other factors that may affect revenue recognition such as potential rebates, ~~which~~chargebacks, isdiscounts, ~~generally~~distribution ~~upon~~fees, ~~execution~~allowances offor apatient ~~purchase~~assistance ~~agreement~~programs, ~~and~~etc. ~~delivery~~will ofbe addressed when the ~~intellectual~~company ~~property~~begins to enter revenue generating agreements and appropriate U.S. GAAP concepts regarding them will be implemented and this policy will be expanded to describe additional considerations related to them.

Intangible Assets

The Company capitalizes the costs of acquiring intellectual property. The Company amortizes these costs over the costs in the same expected ratio as the associated ultimate revenue.

Impairment of Long-Lived Assets

The Company reviews and evaluates long-lived assets for impairment when events or changes in circumstances indicate that the related carrying amounts may not be recoverable. The assets are subject to impairment consideration under ASC 360-10-35-17 if events or circumstances indicate that their carrying amounts might not be recoverable. When the Company determines that an impairment analysis should be done, the analysis will be performed using rules of ASC 930-360-35, Asset Impairment, and 360-10-15-3 through 15-5, Impairment or Disposal of Long-Lived Assets.

Fair Value of Financial Instruments

The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities that are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.

Table of Contents

In accordance with the fair value accounting requirements, companies may choose to measure eligible financial instruments and certain other items at fair value. The Company has not elected the fair value option for any eligible financial instruments. There have been no transfers between fair value levels during the years ended December 31, 2021 and 2020. Financial instruments are measured at amortized cost or at fair value. Financial instruments measured at amortized cost consist of accounts payable, accrued liabilities and income taxes payable wherein the carrying value approximates fair value due to its short-term nature. Other financial instruments measured at amortized cost include notes payables wherein the carrying value at the effective interest rate approximates fair value as the interest rate approximate a market rate for similar instruments offered to the Company.

Income Taxes

The Company provides for income taxes under ASC 740, ~~Accounting for~~ “Income Taxes” (“ASC 740”). ASC 740 requires the ~~use~~recognition of andeferred ~~asset and liability approach in accounting for income taxes. Deferred~~ tax assets and liabilities ~~are~~for ~~recorded~~both ~~based~~the onexpected ~~the~~impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax ~~rates~~benefit into ~~effect~~be ~~when~~derived ~~these~~from ~~differences~~tax ~~are~~loss ~~expected~~and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to ~~reverse~~be established when it is more likely than not that all or a portion of deferred tax assets will not be recognized.

ASC 740 ~~requires~~also classifies the ~~reduction~~accounting offor ~~deferred~~uncertainty ~~tax~~in ~~assets~~income bytaxes recognized in an enterprise’s financial statements and prescribes a ~~valuation~~recognition ~~allowance~~threshold ~~if,~~and ~~based~~measurement onprocess ~~the~~for ~~weight~~financial statement recognition and measurement of ~~available~~a ~~evidence~~tax position taken or expected to be taken in a tax return. For those benefits to be recognized, ita istax position must be more likely than not ~~that~~to ~~some~~be orsustained ~~all~~upon ofexamination ~~the~~by ~~deferred~~taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax ~~assets~~benefits ~~will~~as income tax expenses. The Company is currently not beaware ~~realized~~of any issues under review that could result in significant payments, accruals or material deviation from its position. Through March 31, 2022, there has been no interest expense or penalties related to unrecognized tax benefits.

If applicable, the Company would classify interest and penalties related to uncertain tax positions in income tax expense. Through September 30, 2021, there has been no interest expense or penalties related to unrecognized tax benefits.

Recent Accounting Pronouncements

In ~~May~~August ~~2014~~2018, the FASB issued ASU ~~2014~~2018-0913, ~~“Revenue~~Fair ~~from~~Value ~~Contracts~~Measurement ~~with~~(Topic ~~Customers”~~820) ~~which~~Disclosure ~~supersedes~~Framework—Changes to the ~~most~~Disclosure ~~current~~Requirements ~~revenue~~for ~~recognition~~Fair ~~requirements.~~Value ~~This~~Measurement, ~~ASU~~which ~~requires~~modifies ~~entities~~the todisclosure ~~recognize~~requirements ~~revenue~~on infair avalue ~~way~~measurements. ~~that~~The ~~depicts~~updated ~~the~~guidance ~~transfer~~is ofeffective ~~goods~~for orfiscal ~~services~~years, toand ~~customers~~interim inperiods anwithin ~~amount~~those ~~that~~fiscal ~~reflects~~years, ~~the~~beginning ~~consideration~~after ~~which~~December ~~the~~15, ~~entity~~2019. ~~expects~~Early toadoption beis ~~entitled~~permitted ~~to in exchange~~ for ~~those~~any ~~goods~~removed or ~~services. The Company adopted the pronouncement under the~~ modified ~~retrospective method of transition in the first quarter of 2018~~disclosures. The adoption of ~~the~~this ~~new~~ASU ~~standard~~during ~~did~~the ~~not~~year ~~have~~ended aDecember ~~material~~31, ~~effect~~2020 onhad ~~the~~no ~~overall~~material ~~timing~~impact oron ~~amount~~these offinancial ~~revenue recognized~~statements.

In December 2019, the FASB issued ASU 2019-12, “Simplifying the Accounting for Income Taxes” which eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently evaluating the adoption date and impact, if any, adoption will have on its balance sheets and results of operations.

In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers (Topic 606)” which supersedes the most current revenue recognition requirements. This ASU requires entities to recognize revenue in a way that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the entity expects to be entitled to in exchange for those goods or services. The Company adopted the pronouncement under the modified retrospective method of transition in the first quarter of 2018. The adoption of the new standard did not have a material effect on the overall timing or amount of revenue recognized.

Management has considered all recent accounting pronouncements issued since the last audit of the Company’s financial statements. The Company’s management believes that these recent pronouncements will not have a material effect on the Company’s financial statements.

8 Table of Contents

2. GOING CONCERN

The Company's financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has a limited operating history and has not yet established strong liquidity or a reliable ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern over an extended period of time. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until its operations become established enough to be considered reliably profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses. The Company intends to position itself so that it may be able to raise additional funds through the capital markets. In light of management’s efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern.

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. These factors raise substantial doubts about the Company’s ability to continue as a going concern for one year from the issuance date from these financial statements. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

3. STOCKHOLDERS’ EQUITY

On April 7, 2021, in connection with the sale of the company to Phoenixus by Wookey, the 1 million shares of restricted common stock that were given to Gary Allen, who served as a member of the Board of Directors of the Company from February 27, 2020 to March 27, 2020, on March 27, 2020 in consideration for services rendered and agreed to be rendered by Mr. Allen to the Company, were returned by Mr. Allen and cancelled. The expense which was recorded in March of 2020 was reversed and recorded as Other Income in April of 2021.

As of September 30, 2021, the Company has authorized 80,000,000 shares of $0.001 par value common stock, of which 22,950,000 shares are issued and outstanding.

4. RELATED PARTY TRANSACTIONS

During the year ended December 31, 2020, the Company paid $6,877 to its President and Chief Executive Officer as compensation for executive services rendered through June 30, 2020. Additionally, Wookey, a related party, made payments on behalf of the Company for trade accounts payable during the year ended December 31, 2020 and also during 2021 until the acquisition by Phoenixus. In connection with the sale of the Company by Wookey to Phoenixus in April of 2021, and receipt by Wookey of the proceeds from the sale, Wookey Project and Wookey Search forgave the outstanding balances owed to them by the Company and the balance in Due to Related Party was eliminated with a corresponding amount recorded in Other Income for the forgiveness of debt. Phoenixus has made payments on behalf of the Company since acquiring it. During the three months ended September 30, 2021, SevenScore Pharmaceuticals, LLC, a Delaware limited liability company and U.S. based subsidiary of Phoenixus (“SevenScore”), made payments of $88,397 on behalf of the company. The accounts payable-related party balance is $95,397 at September 30, 2021 and was $48,570 at December 31, 2020.

On May 13, 2021, the Company, entered into an Agreement and Plan of Merger (the “Merger Agreement”) with SevenScore. On September 1, 2021, the Merger Agreement was terminated by mutual agreement of the Company and SevenScore. No fees or penalties were paid in connection with the termination of the Merger Agreement, and both parties provided releases of liability with respect to the termination of the Merger Agreement.

9 Table of Contents

5. INCOME TAXES

Income tax expense consists of the following:

	September 30,
	2021		2020
Federal	$	-	$	-
State		-
Total	$	-	$	-

Income tax expense differed from the amounts computed by applying the U.S. federal statutory tax rate applicable to the Company’s level of pretax income as a result of the following:

	September 30,
	2021		2020
Federal tax at statutory rate	$	-	$	-
State taxes, net of federal benefit		-		-
Net operating loss carryforward		-		-
Total	$	-	$	-

6. CONCENTRATION

For the period from January 1, 2020, to September 30, 2021, revenues consisted of sales to one customer.

7. SUBSEQUENT EVENTS

On April 7, 2021, Wookey Technologies Corporation, a Delaware corporation, the previous majority shareholder of the Company, entered into a stock purchase agreement for the sale of 20,000,000 shares of Common Stock of the Company, to Phoenixus, an accredited investor. Phoenixus also acquired an additional 2,680,000 shares of common stock from three minority shareholders. In connection with the sale of such shares, an aggregate of 1,000,000 shares of common stock held by Gary Allen were returned to the Company for cancellation. As a result of the acquisition of 22,680,000 shares of common stock and the cancellation of 1,000,000 shares, Phoenixus holds approximately 99% of the issued and outstanding shares of Common Stock of the Company, and as such it is able to unilaterally control the election of our board of directors, all matters upon which shareholder approval is required and, ultimately, the direction of the Company.

Also, on April 7, 2021, Mark Gustavson, Chief Executive Officer, Secretary and Director of the Company, and Ross Meador, Vice President and General Counsel of the Company, resigned their positions with the Company. Upon such resignations, Anne Kirby was appointed as Chief Executive Officer, President and sole Director. Rob Stubblefield remains the Chief Financial Officer of the Company.

On May 13, 2021, the Company, entered into the Merger Agreement with SevenScore. On September 1, 2021, the Merger Agreement was terminated by mutual agreement of the Company and SevenScore. No fees or penalties were paid in connection with the termination of the Merger Agreement, and both parties provided releases of liability with respect to the termination of the Merger Agreement. Notification to FINRA about the merger and intention to change the name of the Company to SevenScore Pharmaceuticals, Inc. was withdrawn in September.

On October 8, 2021, Regnum issued a convertible promissory note in the principal amount of $1,500,000 to its principal shareholder, Phoenixus to support clinical development and general expenses. The principal will bear interest at the rate of 3% per annum, payable on maturity or conversion. The note will mature 365 days following the date of issue, unless earlier repurchased or converted. Phoenixus has an option to convert the principal and interest into common shares of Regnum at $0.40 per share, upon Regnum completing an equity financing of at least an additional $5,000,000 in the aggregate.

The Company has submitted a Company Related Action Notification in accordance with Financial Industry Regulatory Authority (FINRA) Rule 6490 (the “Corporate Action Notice”) on October 20, 2021, in connection with a proposed change of the Company’s name to Rovida Therapeutics, Inc. and the redomicile of the Company from Nevada to Delaware. The Corporate Actions have been approved by the board of directors of the Company and by holders of a majority of the outstanding shares of common stock of the Company. The Corporate Actions will be effectuated immediately following FINRA’s review thereof.

In accordance with SFAS 165 Company management reviewed all material events through the date of this report and there are no additional material subsequent events to report.

Table of Contents

~~ITEM~~NOTE 23. ~~MANAGEMENT~~STOCKHOLDERS’S ~~DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS~~ EQUITY

~~The~~As ~~following discussion~~ of ~~the~~March ~~Company’s~~31, ~~historical~~2022, ~~performance and financial condition should be read together with~~ the ~~financial~~Company ~~statements~~had 80,000,000 ~~and~~authorized ~~related~~shares ~~notes in “Item 1. Financial Statements”~~ of ~~this~~Common ~~Report.~~Stock, ~~This discussion contains forward-looking statements based on the views and beliefs~~ of ~~our~~which ~~management~~22,950,000 asshares ~~well as assumptions and estimates made by our management. These statements by their nature~~ are ~~subject~~issued ~~to risks~~ and ~~uncertainties~~outstanding ~~and~~at ~~are~~such ~~influenced by various factors~~date. ~~As a consequence, actual results may differ materially from those in the forward-looking statements. See “Item 1A. Risk Factors” of this report for the discussion of risk factors.~~

~~Plan~~NOTE of4. ~~Operations~~RELATED PARTY TRANSACTIONS

WeAccounts had working capital of <$114,965> as of September 30, 2021. We anticipate the need for additional funding in order to continue our operations at their current levels, and to pay the costs associated with being a public company. As announced on April 7, 2021, we may also require additional funding in the future to expand or complete acquisitions. In the event we require additional funding, we plan to raise that through the sale of debt or equity, which may not be available on favorable terms, if at all, and may, if sold, cause significant dilution to existing stockholders. If we are unable to access additional capital moving forward, it may hurt our ability to grow and to generate future revenues. Payable

WeDuring ~~reiterate~~the ~~that~~year ended December 31, 2021, in connection with the sale of a majority stake in the Company’s ~~business~~by ~~plan~~Wookey ~~changed~~Search ~~significantly~~Technologies ~~and~~Corporation ~~materially~~(“Wookey”) to Phoenixus in April of 2021, ~~during~~and ~~the~~receipt ~~period~~by ~~for~~Wookey ~~which~~of the ~~financial~~proceeds ~~statements~~from ~~presented~~the ~~hereby~~sale, ~~cover~~Wookey Project Corp. Asand aWookey ~~result,~~forgave ~~these~~the ~~results~~outstanding dobalances ~~not~~owed ~~represent~~to them by the Company’s ~~potential~~and ~~results~~the balance in Due to Related Party was eliminated with a corresponding amount recorded in Other Income for the ~~future~~forgiveness of debt. Vyera Pharmaceuticals, LLC (“Vyera”), and SevenScore Pharmaceuticals, LLC (“SevenScore”), each of which are subsidiaries Phoenixus, made payments on behalf of the Company between April and October of 2021, which have been recorded as accounts payable - related party.

~~RESULTS~~The OFaccounts ~~OPERATIONS~~payable-related party balance was $520,937 and $339,179 as of March 31, 2022 and December 31, 2021, respectively.

~~Results~~On ofMay ~~Operations~~13, ~~for~~2021, the ~~Nine~~Company ~~months~~entered ~~ended~~into an Agreement and Plan of Merger (the “Merger Agreement”) with SevenScore. On September 301, 2021, ~~compared~~the toMerger Agreement was terminated by mutual agreement of the ~~Nine~~Company ~~months~~and ~~Ended~~SevenScore. ~~September~~No 30fees or penalties were paid in connection with the termination of the Merger Agreement, ~~2020~~and both parties provided releases of liability with respect to the termination of the Merger Agreement.

WeThe ~~had~~Company nois ~~revenue~~party ~~for~~to the ~~nine~~following ~~months~~service ~~ended~~agreements ~~September~~with ~~30,~~Vyera ~~2021~~(together, ~~compared~~the ~~with~~“Shared $6Services Agreements”): (i) a Management and Business Consulting Agreement,~~750~~ ~~for~~wherein Vyera is the ~~nine~~service ~~months~~provider; ~~ended~~(ii) ~~September~~a ~~30,~~Shared ~~2020~~Services Agreement; and (iii) a Research and Development Services Agreement. ~~The~~Through ~~decrease~~these inagreements, ~~revenue~~Regnum ~~was~~can ~~the~~receive ~~result~~and ofprovide ageneral ~~change~~and inadministrative support, and Regnum is able to receive management level business ~~model~~strategy inconsulting ~~2021~~and asresearch ~~Wookey~~and ~~sold~~development ~~the~~services. ~~controlling~~Services ~~shares~~are invoiced to ~~Phoenixus~~each party at an arm’s length markup.

~~Our~~During ~~operating expenses for~~ the ~~nine~~quarter ~~months~~ ended ~~September~~March 3031, ~~2021,~~2022 ~~were $113,995 which consisted of $67,180 for legal~~ and ~~professional fees and general and administrative expenses of $46,815. For~~ the ~~nine~~year ~~months~~ ended ~~September~~December 2031, ~~2020 operating expenses were $121~~2021,~~478~~ ~~which~~a ~~consisted~~total of $3155,~~757~~957 ~~for amortization of intangibles, legal~~ and ~~professional fees of~~ $53164,~~249~~874, ~~and general and administrative expenses of $64~~respectively,~~472.~~ ~~The~~were incurred by ~~majority of legal and professional fees following~~ the ~~acquisition~~Company ~~by Phoenixus were related~~ to ~~the~~Vyera ~~previously~~under ~~contemplated~~these ~~merger~~service ~~with~~agreements ~~SevenScore~~ and ~~costs~~recorded ~~associated with due diligence~~ in ~~evaluating~~accounts ~~certain~~payable ~~assets.~~– ~~The~~related ~~decrease in general and administrative expenses in 2021 is because the expense for 1 million shares granted to Gary Allen in 2020 was nonrecurring~~party.

~~When~~On 1October ~~million~~8, ~~shares~~2021, ofthe ~~stock~~Company ~~which~~received ~~had~~a ~~been~~loan ~~granted~~in tothe ~~Gary~~principal ~~Allen~~amount inof ~~2020~~$1,500,000 ~~were~~from ~~cancelled~~its ~~and~~principal ~~returned~~shareholder, Phoenixus, to ~~the~~support ~~company~~clinical indevelopment ~~connection~~and ~~with~~general ~~the~~expenses. ~~sale~~The toloan ~~Phoenixus~~is instructured ~~2021,~~as ~~the~~a ~~previous~~convertible ~~expense~~promissory ofnote ~~$59,600~~and ~~was~~bears ~~reversed~~interest ~~and~~at ~~recorded~~the asrate ~~Other~~of ~~Income.~~3% ~~Additionally~~per annum, ~~the~~payable ~~forgiveness~~on bymaturity ~~Wookey~~or ~~Project~~conversion. ~~Corp~~The &note ~~Wookey~~will ~~Search~~mature ~~Technologies~~365 ~~Corporation~~days following the date of ~~$49~~issue,~~423~~ ~~which~~unless ~~had~~earlier ~~previously~~repurchased ~~been~~or ~~recorded~~converted. asPhoenixus ~~Due~~has an option to ~~Related~~convert ~~Party~~the ~~has~~principal ~~also~~and ~~been~~interest ~~recorded~~into inshares ~~Other~~of ~~Income~~Common ~~for~~Stock ~~2021~~at $0.40 per share, upon Regnum completing an equity financing of at least an additional $5,000,000 in the aggregate.

At March 31, 2022 and December 31, 2021, the balance of this note, including accrued interest, was $1,521,575 and $1,510,479, respectively.

Other Commitments

On January 3, 2022, Regnum, CytoDyn, and SevenScore entered into an Assignment and Assumption Agreement (“Assignment”) of the Commercialization and License Agreement (the “License Agreement”) and a Supply Agreement (the “Supply Agreement”) executed between Vyera and CytoDyn on December 17, 2019. Through the Assignment, Regnum has the exclusive right to commercialize pharmaceutical preparations containing leronlimab (PRO 140) (the “Product”) for treatment of HIV in humans in the United States. In exchange for these agreements, SevenScore is entitled to receive 4,094,023 shares of Common Stock.

Table of Contents

~~The~~NOTE ~~Company had a net loss of $4,972 for the nine months ended September 30, 2021, compared to net loss of $116,956 for the nine months ended September 30, 2020~~5. ~~The~~INCOME decrease in net loss is primarily because the expense for granting stock to Gary Allen in 2020 was reversed in April of 2021 when those shares were returned and cancelled in connection with the sale of Regnum to Phoenixus. Additionally, amounts paid in 2020 on behalf of Regnum by Wookey Project Corp & Wookey Search Technologies Corporation, both related parties, were forgiven upon sale of Regnum to Phoenixus in April of 2021.TAXES

~~Liquidity~~Income ~~and~~tax ~~Capital~~expense ~~Resources~~consists of the following:

The Company’s cash position was $0 on September 30, 2021, and on September 30, 2020. For nine months ended September 30, 2021, the company’s cash needs were met via payments made on its behalf by Wookey Project Corp, and SevenScore which are related parties of the company and were recorded as accounts payable – related party. Upon the sale of the Company to Phoenixus, Wookey forgave the amounts paid on behalf of the Company and those liabilities were removed from the Company’s accounting records. Since acquiring the Company, SevenScore, a U.S. subsidiary of Phoenixus, has made payments on behalf of the Company for accounting and audit services, legal fees, and consulting services totaling $95,397 which has been recorded as Due to Related Party at September 30, 2021. As of September 30, 2021, the Company had current assets of $4,000 and current liabilities of $118,965 compared to $4,500 and $54,893, respectively, as of December 31, 2020. This resulted in working capital of <$114,965> on September 30, 2021, and <$50,393> on December 31, 2020.

	March 31,
	2022		2021
Federal	$	-	$	-
State		-		-
Total	$	-	$	-

~~Net~~Income ~~cash~~tax ~~used~~expense indiffered ~~operating~~from ~~activities~~the ~~amounted~~amounts tocomputed $0by ~~for~~applying the ~~nine~~U.S. ~~months~~federal ~~ended~~statutory ~~September~~tax ~~30,~~rate ~~2021,~~applicable ~~compared~~ to ~~using~~the ~~net~~Company’s ~~cash~~level of ~~$7,444~~pretax ~~for~~income ~~the~~as ~~nine~~a ~~months~~result ~~ended~~of ~~September~~the ~~30, 2020.~~ following:

Net cash used in investing activities was $0 for the nine months ended September 30, 2021 and $3,772 for the nine months ended September 30, 2020.

	March 31,
	2022		2021
Federal tax at statutory rate	$	-	$	-
State taxes, net of federal benefit		-		-
Net operating loss carryforward		-		-
Total	$	-	$	-

~~Net~~NOTE ~~cash provided by financing activities was $0 for the nine months ended September 30, 2021 and 2020~~6. CONCENTRATION

WeThe doCompany ~~not~~ currently ~~have~~relies ~~any~~on ~~additional~~CytoDyn, ~~commitments~~our orsupply ~~identified~~partner, ~~sources~~for ~~of additional capital from third parties or from our officers~~development, ~~directors~~manufacture, orand ~~majority~~supply ~~stockholders.~~of ~~Additional~~all ~~financing~~commercial ~~may~~grade ~~not~~quantities beof ~~available~~the ~~on favorable terms, if at all~~Product.

InNOTE the future, we may be required to seek additional capital by selling additional debt or equity securities, or otherwise be required to bring cash flows in balance when we approach a condition of cash insufficiency7. ~~The~~CHANGE ~~sale~~IN ofCONTROL ~~additional~~OF ~~equity~~THE or debt securities, if accomplished, may result in dilution to our then stockholders. Financing may not be available in amounts or on terms acceptable to us, or at all. In the event we are unable to raise additional funding and/or obtain revenues sufficient to support our expenses, we may be forced to curtail or abandon our business operations, and any investment in the Company could become worthless.COMPANY

~~Off-Balance~~On ~~Sheet~~April ~~Arrangements~~7, 2021, Wookey, the previous majority shareholder of the Company, entered into a stock purchase agreement for the sale of 20,000,000 shares of Common Stock to Phoenixus, an accredited investor. Phoenixus also acquired an additional 2,680,000 shares of Common Stock from three minority shareholders. In connection with the sale of such shares, an aggregate of 1,000,000 shares of Common Stock held by Gary Allen (a former director of the Company) were returned to the Company for cancellation.

WeAs doa ~~not~~result ~~have~~of ~~any~~the ~~off-balance~~acquisition ~~sheet~~of ~~arrangements~~22,680,000 shares of Common Stock, and the cancellation of 1,000,000 shares, Phoenixus holds approximately 99% of the issued and outstanding shares of Common Stock, and as such it is able to unilaterally control the election of the Company's board of directors, all matters upon which shareholder approval is required and, ultimately, the direction of the Company.

NOTE 8. COMMITMENTS AND CONTINGENCIES

Contingencies

The Company’s operations are subject to a variety of local, state, and federal regulation. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations.

Litigation and Claims

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of March 31, 2022, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company’s operations.

NOTE 9. SUBSEQUENT EVENTS

The Company evaluates events and transactions subsequent to March 31, 2022 through the date of this filing to assess the need for potential recognition or disclosure. Based upon this review, the Company did not identify any subsequent events that require adjustment or disclosure in the financial statements.

Table of Contents

~~Critical~~ITEM ~~Accounting~~2. ~~Policies~~MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

~~Our~~Cautionary ~~discussion~~Note ~~and~~Regarding analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We monitor our estimates on an onForward-~~going~~Looking basis for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are recorded in the period in which they become known. We base our estimates on historical experience and other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be substantially accurate.Statements

~~Certain~~This ofQuarterly ~~our~~Report ~~accounting~~on ~~policies~~Form ~~are~~10-Q ~~particularly~~(the ~~important~~“Quarterly toReport”) contains certain “forward-looking statements” within the ~~portrayal~~meaning ~~and~~of ~~understanding~~Section 27A of ~~our~~the ~~financial~~Securities ~~position~~Act of 1933, as amended (the “Securities Act”), and ~~results~~Section 21E of ~~operations~~the ~~and~~Securities ~~require~~Exchange usAct toof ~~apply~~1934, ~~significant~~as ~~judgment~~amended in(the ~~their~~“Exchange ~~application~~Act”). AsThese aforward-looking ~~result,~~statements ~~these~~are ~~policies~~not ~~are~~statements ~~subject~~of tohistorical anfact ~~inherent~~and ~~degree~~involve a number of ~~uncertainty~~risks and uncertainties. InWe ~~applying~~caution ~~these~~the ~~policies,~~readers wethat ~~use~~forward-looking ~~our~~statements ~~judgment~~are innot ~~making~~a ~~certain~~guarantee ~~assumption~~of future performance and ~~estimates~~that actual results could differ materially from those contained in such forward-looking statements. ~~Our~~All ~~critical~~statements, ~~accounting~~other ~~policies~~than ~~are~~statements ~~outlined~~of historical fact included in this Quarterly Report including, without limitation, statements in this “~~Note~~Management’s 1Discussion -and ~~Summary~~Analysis of ~~Significant~~Financial ~~Accounting~~Condition ~~Policies~~and Results of Operations” toregarding the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. ~~included~~Words ~~herein~~such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “plan,” “seek,” “should,” “will,” and variations and other similar words and expressions are intended to identify such forward-looking statements.

~~Critical~~These ~~Accounting~~forward-looking ~~Policies:~~statements are based on the current beliefs and expectations of our management, and are subject to significant risks and uncertainties. If the underlying assumptions prove incorrect or unknown risks or uncertainties materialize, actual results could differ materially from our current expectations. These risks and uncertainties include those factors described in “Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 21, 2021. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those anticipated in these forward-looking statements. All subsequent written or oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in this section. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report.

~~Emerging Growth Company. Section 107 of the Jumpstart Our~~ Business Startups Act of 2012 (the “JOBS Act”) provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.Overview

~~RECENTLY~~Regnum ~~ISSUED~~Corp. ~~ACCOUNTING~~was ~~STANDARDS~~incorporated on March 31, 2016, under the laws of the State of Nevada. The Company was formed for a primary business purpose of servicing the increasing demand for premium entertainment content and becoming a depository of unpublished intellectual properties for resale with focus on achieving profitability and sustaining business growth. Following the acquisition by Phoenixus AG (“Phoenixus”) on April 7, 2021, the Company’s prior business model was abandoned.

~~For~~13 ~~more~~Table ~~information on recently issued accounting standards, see “Note 1 - Summary~~ of ~~Significant Accounting Policies” to the Notes to Financial Statements included herein.~~Contents

~~ITEM~~Business ~~3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK~~Outlook

~~Pursuant~~Since April 2021, the Company’s business model is focused on developing and commercializing therapeutics that treat rare and infectious diseases, specifically in populations that are neglected or face adherence challenges due to ~~Item~~inconvenient ~~305(e)~~dosing ofor ~~Regulation~~delivery ~~S-K~~system, (§tolerability, ~~229~~or cost and accessibility of available therapeutic options.~~305(e))~~ Under certain license and commercial agreements with CytoDyn which were assigned to the Company in January 2022, the Company’s primary asset is ~~not~~the ~~required~~commercial rights to ~~provide~~leronlimab ~~the~~(also ~~information~~known ~~required~~as by“PRO ~~this~~140”) ~~Item~~in asall ithuman immunodeficiency virus (“HIV”) indications within the United States. Leronlimab is the subject of a ~~“smaller~~current ~~reporting~~Biologics ~~company,~~License Application (“BLA”) asthat ~~defined~~has bybeen ~~Rule~~submitted ~~229~~in part to the U.10S. Food and Drug Administration (f“FDA”)~~(1)~~ with an indication to treat Multi-Drug Resistant HIV infection, with the potential for multiple additional therapeutic indications in HIV. As of the date of this report, the FDA’s review of the BLA is ongoing. Since the FDA approval process is ongoing and its outcome is uncertain, we are also seeking to acquire or in-license other pharmaceutical products or product candidates, although no products have been identified to date.

13The ~~Table~~Company is party to the following service agreements with Vyera, which is a subsidiary of ~~Contents~~Phoenixus (together, the “Shared Services Agreements”): (i) a Management and Business Consulting Agreement, wherein Vyera is the service provider; (ii) a Shared Services Agreement; and (iii) a Research and Development Services Agreement. Through these agreements, Regnum can receive and provide general and administrative support, and Regnum is able to receive management level business strategy consulting and research and development services. Services are invoiced to each party at an arm’s length markup. Disruption or interruption of any of these Shared Services Agreements, while not anticipated, could interfere in continuity of our operations.

~~ITEM~~Trends 4.Affecting ~~CONTROLS~~Our ~~AND PROCEDURES~~Business

~~Disclosure~~Our ~~Controls~~industry is highly dynamic and ~~Procedures~~competitive, with technological and scientific innovation paving the way for new products that may transform our industry. We anticipate the recent capital markets downturn in the biotechnology sector to affect our ability to secure additional funding. We do not currently generate revenue from product sales and anticipate we will need additional funding in order to continue our operations at their current levels, to conduct our commercialization activities for leronlimab if it is approved by the FDA, and to pay the costs associated with being a public company, for the next 12 months. To the extent we in-license or acquire additional products or technologies, we will also require additional funding in the future to support our operations. Additional financing may not be available to us on terms that are acceptable or at all.

~~The~~Plan ~~Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company's reports filed under the Securities Exchange Act~~ of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to the Company's management, including the Company's president and chief executive officer (who is the Company's principal executive officer) and the Company's chief financial officer and treasurer (who is the Company's principal financial officer and principal accounting officer) to allow for timely decisions regarding required disclosure. In designing and evaluating the Company's disclosure controls and procedures, the Company's management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and the Company's management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Operations

~~Management's~~We ~~Report~~had negative working capital of $657,425 as of March 31, 2022. We anticipate the need for additional funding in order to continue our operations at their current levels, and to pay the costs associated with being a public company. We may also require additional funding in the future to expand or complete acquisitions. In the event we require additional funding, we plan to raise the necessary funding through the sale of debt or equity, which may not be available on ~~Internal~~favorable ~~Control~~terms, ~~over~~if ~~Financial~~at ~~Reporting~~all, and may, if sold, cause significant dilution to existing stockholders. If we are unable to access additional capital moving forward, it may hurt our ability to grow and to generate future revenues.

~~Management~~We isreiterate ~~responsible~~that ~~for establishing and maintaining adequate internal control over~~ the Company'’s ~~financial~~business ~~reporting.~~plan Inchanged ~~order~~significantly to evaluate the effectiveness of internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act of 2002. Our management, with the participation of the Company's principal executive officer and ~~principal~~materially ~~financial officer has conducted an assessment using the criteria~~ in ~~Internal~~April ~~Control - Integrated Framework~~2021, ~~issued~~during by the ~~Committee~~period offor ~~Sponsoring~~which ~~Organizations of~~ the ~~Treadway~~comparative ~~Commission ("COSO") (2013). Our system of internal control over~~ financial ~~reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial~~ statements ~~for~~presented ~~external~~hereby ~~purposes in accordance with generally accepted accounting principles~~cover. ~~Because~~As ofa ~~its inherent limitations~~result, ~~internal~~financial ~~control~~results ~~over~~for ~~financial~~2021 ~~reporting~~do ~~may~~ not ~~prevent~~represent ~~or detect misstatements. This assessment included review of~~ the ~~documentation~~Company’s ofpotential ~~controls,~~results ~~evaluation~~in of the ~~design effectiveness of controls and a conclusion on this evaluation~~future.

~~Based~~14 onTable ~~this evaluation, the Company's management concluded its internal control over financial reporting was effective as~~ of ~~September 30, 2021.~~ Contents

~~Changes~~RESULTS inOF ~~Internal Control Over Financial Reporting~~OPERATIONS

~~There~~Comparison ~~were~~of ~~no changes in our internal control over financial reporting during~~ the ~~quarter~~three months ended ~~September~~March 3031, ~~2021,~~2022 ~~that have materially affected, or are reasonably likely~~ to ~~materially affect our internal control over financial reporting. We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that~~ the ~~objectives~~three ofmonths ~~the~~ended ~~control~~March ~~system are met~~31, ~~and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within any company have been detected.~~2021

~~14 Table of Contents~~Revenue

~~PART~~We ~~II.~~had ~~OTHER~~no ~~INFORMATION~~revenue for the three months ended March 31, 2022, or March 31, 2021, which was the result of a change in business model as Wookey sold the controlling shares to Phoenixus in April of 2021.

~~ITEM~~Our 1operating expenses for the three months ended March 31, 2022 were $277,602, which consisted of $95,097 for legal and professional fees, general and administrative expenses of $171,409, and interest expense of $11,096. ~~LEGAL~~For ~~PROCEEDINGS~~the three months ended March 31, 2021, operating expenses were $3,340, which consisted of legal and professional fees of $2,860, and general and administrative expenses of $480. The majority of legal and professional fees in the first Quarter of 2022 were related to assignment of Commercial and License Agreement and Supply Agreement, due diligence related to business development efforts, and auditing. The increase in general and administrative expenses is related to services provided under shared services agreements entered in September of 2021.

~~Although~~The weCompany ~~may,~~had ~~from~~a ~~time~~net toloss ~~time~~of $277,602 befor ~~involved~~the inthree ~~litigation~~months ~~and~~ended ~~claims~~March ~~arising~~31, ~~out~~2022, ofas ~~our~~compared ~~operations~~to innet loss of $3,340 for the ~~normal~~three ~~course~~months ofended ~~business~~March 31, we2021. ~~are~~The ~~not~~increase ~~currently~~in anet ~~party~~loss is due to ~~any~~increased ~~material~~expenses for legal ~~proceeding.~~and Inprofessional ~~addition,~~fees weand ~~are~~general ~~not~~and ~~aware~~administrative ofexpenses ~~any~~as ~~material~~the ~~legal~~Company orworks ~~governmental~~to ~~proceedings~~execute ~~against~~its usnew orbusiness ~~contemplated~~model toand beidentify ~~brought~~business ~~against~~development usopportunities.

~~ITEM~~Liquidity ~~1A.~~and ~~RISK~~Capital ~~FACTORS~~Resources

~~Risks~~The ~~Related~~Company’s cash position was $1,400,107 on March 31, 2022, and $0 on March 31, 2021. The increase in cash is the result of funds received in October of 2021 under a promissory note from the Company’s principal shareholder, Phoenixus, to ~~Our~~support ~~Business~~clinical ~~Operations:~~development and general expenses. As of March 31, 2022, the Company had current assets of $1,400,607 and current liabilities of $2,058,032 as compared to $1,488,919 and $1,868,742, respectively, as of December 31, 2021. This resulted in negative working capital of $657,425 on March 31, 2022, and $379,823 on December 31, 2021.

WeNet ~~have~~cash ~~limited~~(used ~~operating~~in) ~~history~~provided ofby ~~the~~operating ~~new line of business. As such, there is no assurance of profitability.~~activities

WeFor ~~have~~the athree ~~limited~~months ~~operating~~ended ~~history~~March ~~and~~31, ~~accordingly~~2022, ~~have~~net acash ~~limited~~used in operating ~~history~~activities onamounted ~~which~~ to ~~base~~$88,312, anas ~~evaluation~~compared ofto ~~our~~using ~~business.~~$0 ~~Our~~net ~~business~~cash ~~must~~for ~~be considered in light of~~ the ~~risks,~~three ~~expenses~~months ~~and~~ended ~~problems~~March ~~frequently encountered by companies in their early stages of development~~31, ~~particularly companies in new and rapidly evolving markets which involve technology~~2021. ~~Our~~The ~~proposed~~increase ~~operations~~in ~~are~~net ~~subject~~cash toused ~~all~~is ofas ~~the risks inherent in the establishment of~~ a ~~new~~result ~~business enterprise. Accordingly, the likelihood~~ of ~~our~~payments ~~success~~made ~~must~~to bethird ~~considered~~parties infor ~~the~~Legal ~~light of the problems, expenses, difficulties, complications,~~ and ~~delays~~Professional ~~frequently encountered in connection with the starting~~ and ~~expansion~~General ~~of a business~~ and ~~the~~Administrative ~~relatively competitive environment in which we will operate~~expenses.

~~Unanticipated~~Net ~~delays,~~cash ~~expenses~~used ~~and other problems such as setbacks~~ in ~~product~~investing development, product manufacturing, and market acceptance are frequently encountered in establishing a new business such as ours. There can be no assurance that the Company will be successful in addressing such risks, and any failure to do so could have a material adverse effect on the Company's business, results of operations and financial condition.activities

~~Because~~Net ofcash ~~our~~used ~~limited operating history, we have limited historical financial data on which to base planned operating expenses. Accordingly, our expense levels, which are, to a large extent, variable, will be based~~ in ~~part~~investing onactivities ~~our~~was ~~expectations~~$0 ~~of future revenues. As a result of the variable nature of many of our expenses, we may be unable to adjust spending in a timely manner to compensate~~ for ~~any unexpected delays in~~ the ~~development~~three ~~and~~months ~~marketing~~ended ofMarch ~~our products or any subsequent revenue shortfall. Any such delays or shortfalls will have an immediate adverse impact on our business~~31, ~~operating~~2022 ~~results~~ and ~~financial condition~~2021.

~~The~~Net ~~Company~~cash ~~has~~used ~~not achieved profitability on a quarterly or annual basis to date. To the extent that net revenue does not grow at anticipated rates or that increases~~ in its operating expenses precede or are not subsequently followed by commensurate increases in net revenue, or that the Company is unable to adjust operating expense levels accordingly, the Company's business, results of operations and financial condition will be materially and adversely affected. There can be no assurance that the Company's operating losses will not increase in the future or that the Company will ever achieve or sustain profitability. We may require additional financing, ~~and we may not be able to raise funds on favorable terms or at all.~~activities

WeNet ~~had working capital of <$114,965> as of September 30, 2021. With our current~~ cash onprovided ~~hand,~~by ~~expected~~financing ~~revenues~~activities ~~and~~was ~~based~~$0 ~~on our current average monthly expenses, we anticipate the need~~ for ~~additional funding in order to continue our operations at their current levels and to pay~~ the ~~costs~~three ~~associated with being a public company, for the next 12~~ months, ~~and~~ended ~~may~~March require additional funding in the future to support our operations and/or may seek to raise additional funding in the future to expand or complete acquisitions. The sources of this capital are expected to be equity investments and notes payable. When we issue equity or convertible debt securities to raise additional funds31, ~~our~~2022 ~~existing stockholders may experience dilution,~~ and ~~the new equity or debt securities may have rights, preferences and privileges senior to those of our existing stockholders~~2021. If we incur additional debt, it may increase our leverage relative to our earnings or to our equity capitalization, requiring us to pay additional interest expenses. We may not be able to obtain financing on favorable terms, or at all, in which case, we may not be able to develop or enhance our products, execute our business plan, take advantage of future opportunities or respond to competitive pressures.

WeNet ~~have net losses from operations and there is substantial doubt about our ability to continue as a going concern. If we are not able to generate positive~~ cash ~~flow,~~(used ~~our~~in) ~~business~~provided ~~operations~~by ~~may~~financing ~~fail.~~activities

~~The~~We ~~Company~~do ~~has~~not ~~reported~~currently ahave ~~net~~any ~~loss~~additional ofcommitments ~~$4,972~~or ~~for~~identified ~~the~~sources ~~nine months ended September 30, 2021 and had an accumulated deficit~~ of $156,465 on September 30, 2021. In addition, the Company has a history of losses. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to meet its obligations in the ordinary course of business is dependent upon its ability to establish profitable operations and obtain additional ~~funds~~capital ~~when~~from ~~needed.~~third Weparties ~~may not be able to generate sufficient revenues to support our operations~~ or ~~continue as a going concern. As a result, the opinion the Company received~~ from ~~its~~our ~~independent registered public accounting firm on its December 31~~officers, ~~2020~~directors, ~~financial~~or ~~statements~~majority ~~contain an explanatory paragraph stating that there is substantial doubt regarding the Company’s ability to continue as a going concern~~stockholders. IfAdditional wefinancing ~~become unable to continue as a going concern, we~~ may ~~have~~not tobe ~~liquidate~~available ~~our assets, and may realize significantly less than the values at which they are carried~~ on ~~our~~favorable ~~financial statements~~terms, ~~and~~if ~~stockholders~~at ~~may lose~~ all ~~or part of their investment in our common stock~~. ~~The accompanying financial statements do not contain any adjustments for this uncertainty.~~

~~The~~In ~~most~~the ~~likely~~future, ~~source~~we ofmay ~~future~~be ~~funds~~required ~~presently~~to ~~available~~seek toadditional uscapital ~~will~~by selling additional debt or equity securities, or otherwise be ~~through~~required ~~the~~to ~~sale~~bring cash flows in balance when we approach a condition of ~~equity~~cash ~~capital~~insufficiency. ~~Any~~The sale of ~~share~~additional ~~capital~~equity ~~will~~or debt securities, if accomplished, may result in dilution to ~~existing~~our then stockholders. ~~Furthermore,~~Financing we may ~~incur~~not ~~debt~~be available in amounts or on terms acceptable to us, or at all. In the ~~future~~event ~~and~~we ~~may~~are ~~not~~unable ~~have~~to ~~sufficient~~raise ~~funds~~additional funding and/or obtain revenues sufficient to ~~repay~~support our ~~future~~expenses, ~~indebtedness~~we or may ~~default~~be onforced ~~our~~to ~~future~~curtail ~~debts,~~or ~~jeopardizing~~abandon our business ~~viability~~operations, and any investment in the Company could become worthless.

Table of Contents

WeCritical ~~may~~Accounting not be able to borrow or raise additional capital in the future to meet our needs or to otherwise provide the capital necessary to expand our operations and business, which might result in the value of our common stock decreasing in value or becoming worthless. Additional financing may not be available to us on terms that are acceptable. Consequently, we may not be able to proceed with our intended business plans. Substantial additional funds will still be required if we are to reach our goals that are outlined in this Report. Obtaining additional financing contains risks, including:Policies

·Our ~~additional~~discussion ~~equity~~and ~~financing~~analysis ~~may~~of ~~not~~our befinancial ~~available~~condition toand usresults onof ~~satisfactory~~operations ~~terms~~are ~~and~~based ~~any~~upon ~~equity~~our wefinancial ~~are~~statements, ~~able~~which tohave ~~issue~~been ~~could~~prepared ~~lead~~in toaccordance ~~dilution~~with ~~for~~U.S. ~~current~~GAAP. ~~stockholders;~~The ·preparation ~~loans~~of orthese ~~other~~financial ~~debt~~statements ~~instruments~~requires ~~may~~us ~~have~~to ~~terms~~make assumptions, estimates and~~/or~~ ~~conditions,~~judgments ~~such~~that asaffect ~~interest~~the ~~rate~~reported amounts of assets, ~~restrictive~~liabilities, ~~covenants~~revenues and ~~control~~expenses, orand ~~revocation~~related ~~provisions,~~disclosure ~~which~~of ~~are~~contingent ~~not~~assets ~~acceptable~~and toliabilities. ~~management~~We ormonitor our ~~sole~~estimates ~~Director;~~on ·an ~~the~~ongoing ~~current~~basis ~~environment~~for changes in ~~capital~~facts ~~markets~~and ~~combined~~circumstances, ~~with~~and ~~our~~material ~~capital~~changes ~~constraints~~in ~~may~~these ~~prevent~~estimates uscould ~~from~~occur ~~being~~in ~~able~~the tofuture. ~~obtain~~Changes ~~adequate~~in ~~debt~~estimates ~~financing;~~are ~~and~~recorded ·in ifthe weperiod ~~fail~~in towhich ~~obtain~~they ~~required~~become ~~additional~~known. ~~financing~~We tobase ~~grow~~ our ~~business,~~estimates weon ~~will~~historical ~~need~~experience toand ~~delay~~other orassumptions ~~scale~~that ~~back~~we ~~our~~believe ~~business~~to ~~plan,~~be ~~reduce~~reasonable ~~our~~under ~~operating~~the ~~costs~~circumstances. orActual ~~reduce~~results ~~our~~may ~~headcount,~~differ ~~each~~from ofour ~~which~~estimates ~~would~~if ~~have~~past aexperience ~~material~~or ~~adverse~~other ~~effect~~assumptions ondo ~~our~~not ~~business,~~turn ~~future~~out ~~prospects~~to ~~and~~be ~~financial~~substantially ~~condition~~accurate.

~~Future~~Certain ~~sales~~ of our ~~securities~~accounting ~~could~~policies ~~adversely~~are ~~affect~~particularly important to the ~~market~~portrayal ~~price~~and understanding of our ~~common~~financial ~~stock~~position and ~~our~~results ~~future~~of ~~capital-raising~~operations ~~activities~~and ~~could~~require ~~involve~~us ~~the~~to ~~issuance~~apply ofsignificant ~~equity~~judgment ~~securities~~in their application. As a result, ~~which~~these ~~would~~policies ~~dilute~~are ~~existing~~subject ~~shareholders’~~to ~~investment~~an ~~and~~inherent ~~could~~degree ~~result~~of inuncertainty. aOur ~~decline~~critical accounting policies are outlined in ~~the~~“Note ~~trading~~1 ~~price~~- Summary of ~~our~~Significant ~~common~~Accounting ~~stock~~Policies” to the financial statements included elsewhere in this Quarterly Report.

~~The~~Emerging ~~Company~~Growth ~~may sell securities in the public or private equity markets if and when conditions are favorable, or at prices per share below the current market price of our common stock. The~~ Company ~~may issue additional shares of common stock in future financing transactions or as incentive compensation for our executive management and other key personnel, consultants, and advisors.~~

We Section ~~rely~~107 onof ~~key~~the ~~personnel~~Jumpstart ~~and,~~Our ifBusiness weStartups ~~are~~Act ~~unable~~of to2012 ~~retain~~(the or“JOBS ~~motivate~~Act”) ~~key~~provides ~~personnel~~that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or ~~hire~~revised ~~qualified~~accounting ~~personnel~~standards. In other words, wean “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be ~~able~~comparable to ~~grow~~those ~~effectively~~of companies that comply with such new or revised accounting standards.

~~Our~~Recently ~~success~~Issued ~~depends~~Accounting in large part upon the abilities and continued service of our executive officers and other key employees. There can be no assurance that we will be able to retain the services of such officers and employees. Our failure to retain the services of our key personnel could have a materially adverse effect on our business. In order to support our projected growth, we will be required to effectively recruit, hire, train and retain additional qualified management personnel. Our inability to attract and retain the necessary personnel could have a materially adverse effect on our business. Standards

~~Our~~For ~~ability~~more toinformation ~~grow~~on ~~and~~recently ~~compete~~issued inaccounting ~~the~~standards, ~~future~~see ~~will~~“Note be1 ~~adversely~~- ~~affected~~Summary ifof ~~adequate~~Significant ~~capital~~Accounting isPolicies” ~~not~~to ~~available~~the financial statements included elsewhere in this Quarterly Report.

~~The~~ITEM ability of our business to grow and compete depends on the availability of adequate capital, which in turn depends in large part on our cash flow from operations and the availability of equity and debt financing3. ~~Our~~QUANTITATIVE ~~cash~~AND ~~flow~~QUALITATIVE ~~from~~DISCLOSURES ~~operations~~ABOUT ~~may~~MARKET ~~not be sufficient or we may not be able to obtain equity or debt financing on acceptable terms or at all to implement our growth strategy~~RISK. As a result, adequate capital may not be available to finance our current growth plans, take advantage of business opportunities or respond to competitive pressures, any of which could harm our business.

16As ~~Table~~a of“smaller ~~Contents~~reporting company,” we are not required to provide the information required by this Item 3.

IfITEM we4. ~~are~~CONTROLS ~~unable~~AND ~~to manage future growth effectively, our profitability and liquidity could be adversely affected~~PROCEDURES.

~~Our~~Evaluation ability to achieve our desired growth depends on our execution in functional areas such as management, sales and marketing, finance, general administration and operations. To manage any future growth, we must continue to improve our operational and financial processes and systems and expand, train, and manage our employee base and control associated costs. Our efforts to grow our business, both in terms of ~~size~~Disclosure ~~and~~Controls ~~in diversity of customer bases served, will require expansion in certain functional areas~~ and put a significant strain on our resources. We may incur significant expenses as we attempt to scale our resources and make investments in our business that we believe are necessary to achieve long-term growth goals. If we are unable to manage our growth effectively, our expenses could increase without a proportionate increase in revenue, our margins could decrease, and our business and results of operations could be adversely affected.Procedures

WeThe ~~rely~~Company onmaintains ~~our~~disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company’s reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including the Company’s President and ifChief ~~they~~Executive ~~were~~Officer (who is the Company’s Principal Executive Officer) and the Company’s Chief Financial Officer and Treasurer (who is the Company’s Principal Financial Officer and Principal Accounting Officer) to ~~leave~~allow ~~our~~for ~~company~~timely ~~our~~decisions ~~business~~regarding ~~plan~~required ~~could~~disclosure. beIn ~~adversely~~designing ~~affected~~and evaluating the Company’s disclosure controls and procedures, the Company’s management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and the Company’s management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

We16 ~~are~~Table ~~largely dependent upon the personal efforts and abilities~~ of our existing management, including Ms. Anne Kirby, our Chief Executive Officer, and Mr. Robert J. Stubblefield, our Chief Financial Officer and Treasurer, each of whom plays an active role in our operations. Moving forward, should the services of any of such persons be lost for any reason, the Company will incur costs associated with recruiting replacements and any potential delays in operations which this may cause. If we are unable to replace such individual with a suitably trained alternative individual(s), we may be forced to scale back or curtail our business plan.Contents

WeManagement’s doReport ~~not currently have any employment agreements or maintain key person life insurance policies~~ on ~~our~~Internal ~~executive~~Control ~~officers.~~over Financial Reporting

WeAs dorequired ~~not~~by ~~currently~~Rules ~~have~~13a-15 ~~any~~and ~~employment~~15d-15 ~~agreements~~under the Exchange Act, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2022. Based upon their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as such are defined under Rules 13a-15(e) and 15d-15(e) of the Exchange Act) were effective as of March 31, 2022. Our system of internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in ~~place~~accordance with ~~management~~U.S. GAAP.

~~The~~Changes ~~Company~~in ~~has~~Internal ~~not~~Control ~~entered~~Over ~~into an employment agreement with Ms. Anne Kirby, our Chief Executive Officer, or Mr. Robert J. Stubblefield, our Chief~~ Financial Officer. As such, there are no contractual relationships guaranteeing that Ms. Anne Kirby or Mr. Stubblefield will stay with the Company and continue its operations. In the event any of such persons were to resign, the Company may be unable to get another officer to fill the void and performance may be significantly affected.Reporting

WeOur ~~use~~management, awith ~~centralized~~the ~~services~~participation ~~model~~of our Chief Executive Officer and our Chief Financial Officer, performed an evaluation to ~~compete~~determine ~~operationally~~whether any changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) occurred during the three-month period ended March 31, 2022. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that no change occurred in the Company’s internal control over financial reporting during the three-month period ended March 31, 2022, that has materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

~~The~~Limitations ~~Company and its Affiliates rely~~ on aEffectiveness ~~centralized services model whereby an affiliate provides services pursuant to services agreements to the Phoenixus subsidiaries. This is intended to provide economies~~ of scale across the group of companies and allow individual subsidiaries to keep internal resources lean and, accordingly, be competitive. Should this centralized services model be insufficiently robust, prove ineffective or not be cost effective, there could be a detrimental effect on the business of the Company and its prospects. The centralized services model as applied to the Company is new and, accordingly, relatively untested. Control

Our ~~majority~~management, ~~stockholder~~including our Chief Executive Officer and our Chief Financial Officer, does not expect that our disclosure controls ~~most~~and ofprocedures or our ~~voting~~internal ~~securities~~controls will prevent all errors and ~~therefore~~all ~~has~~fraud. We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the ~~ability~~objectives toof ~~influence~~the ~~matters~~control ~~affecting~~system ~~our~~are ~~stockholders~~met. Further, we believe that because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected.

~~Phoenixus,~~17 ~~our~~Table ~~majority stockholder, which holds approximately 99%~~ of our outstanding shares of common stock, has the ability, to influence matters affecting our stockholders and will therefore exercise control in determining the outcome of all corporate transactions or other matters, including the election of directors, mergers, consolidations, the sale of all or substantially all of our assets, and also the power to prevent or cause a change in control. Any investor who purchases shares will be a minority stockholder and as such will have little to no say in the direction of the Company and the election of directors. Additionally, it will be difficult if not impossible for investors to remove our current Director, which will mean she will remain in control of who serves as officers of the Company as well as whether any changes are made in the Board of Directors. As a potential investor in the Company, you should keep in mind that even if you own shares of the Company’s common stock and wish to vote them at annual or special stockholder meetings, your shares will likely have little effect on the outcome of corporate decisions. Investors may find it difficult to replace our management if they disagree with the way our business is being operated. Contents

17PART ~~Table~~II. ofOTHER ~~Contents~~INFORMATION

~~Our~~ITEM ~~officers~~1. ~~and~~LEGAL ~~directors lack experience in and with publicly traded companies~~PROCEEDINGS.

MsNone. Anne Kirby, our Chief Executive Officer, has not served as an officer or director of a publicly traded company. Mr. Robert J. Stubblefield, our Chief Financial Officer, has served in senior level financial, accounting, and operations roles for public companies. However, Mr. Stubblefield has limited experience with the financial accounting and preparation requirements of financial statements which we are required to file on a quarterly and annual basis under the Exchange Act and will rely on outside legal advisors for guidance regarding such requirements. We plan to initially rely on outside accountants and bookkeepers to help us create a system of accounting controls and procedures to maintain the Company’s accounting records with appropriate internal controls. As a result of the above, our operations, earnings and ultimate financial success could suffer irreparable harm due to our executives’ inexperience with publicly traded companies and especially in connection with the financial accounting and preparation requirements of the Exchange Act.

~~There~~ITEM is1A. noRISK ~~guarantee that Regnum will be able to in-license or acquire rights to clinical programs or commercial drugs in the future~~FACTORS.

~~The~~ Not ~~Company’s~~required ~~business~~for ~~strategy is to build~~ a ~~portfolio~~smaller ofreporting ~~clinical and commercial product candidates through acquisition, licensing, and partnership~~company. Regnum’s success will depend on the Company’s ability to identify assets that are attractive to investors and negotiate favorable transaction terms. Failure to identify appropriate assets or being unable to acquire and then develop them on favorable terms successfully would significantly and materially adversely affect the prospects of the Company

~~Risks~~ITEM of2. ~~Operating~~UNREGISTERED inSALES ~~the~~OF ~~Pharmaceutical~~EQUITY ~~Industry:~~SECURITIES AND USE OF THE PROCEEDS.

~~The pharmaceutical industry is highly regulated and compliance with government regulations can be costly~~None.

~~The~~ITEM research, development, testing, manufacture, quality control, packaging, labeling, storage, record-keeping, distribution, import, export, promotion, advertising, marketing, sale, pricing and reimbursement of pharmaceutical products are extensively regulated by governmental authorities in the United States and other countries3. ~~The~~DEFAULTS ~~processes~~UPON ~~for~~SENIOR obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory requirements, both pre-approval and post-approval, require the expenditure of substantial time and financial resourcesSECURITIES. The regulatory requirements applicable to product development, approval and marketing are subject to change, and regulations and administrative guidance often are revised or reinterpreted by the agencies in ways that may have a significant impact on our business.

~~Licensure and regulation of pharmaceutical and biologic products in the United States can increase risk and uncertainty~~None.

InITEM the United States, the FDA regulates human drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and in the case of biological products, also under the Public Health Service Act, or the PHSA, and their implementing regulations4. ~~The~~MINE ~~failure~~SAFETY ~~to comply with the applicable U~~DISCLOSURES.S. requirements may result in FDA refusal to approve New Drug Applications (NDAs) or Biologic License Applications (BLAs) or delays in development and may subject an applicant to administrative or judicial sanctions, such as issuance of warning letters, or the imposition of fines, civil penalties, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or civil or criminal prosecution brought by the FDA and the U.S. Department of Justice or other governmental entities.

~~The~~Not ~~FDA must approve our product candidates for therapeutic indications before they may be marketed in the United States~~applicable.

~~Regnum~~ITEM ~~will~~5. beOTHER ~~reliant upon third parties, such as Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs)~~INFORMATION.

~~Regnum,~~None. ~~like~~[NOTE: ~~other~~we ~~newly~~might ~~established~~want ~~pharmaceutical companies, will need~~ to ~~contract~~talk ~~with~~about ~~CROs~~FINRA ~~for~~ruling ~~clinical development support. Regnum does not own or operate manufacturing facilities capable of drug manufacturing. As such, the Company must depend on third-party manufacturing organizations~~ and ~~suppliers~~appeal ~~for~~here ~~drug~~if ~~substance,~~more ~~drug~~detail ~~product,~~is ~~and commercial grade product.~~desired]

Table of Contents

~~Pharmaceutical~~ITEM ~~industry is subject to intense competition~~6. ~~If we are unable to compete effectively, the Company’s future product candidate that it develops may be rendered noncompetitive or obsolete~~EXHIBITS.

The ~~pharmaceutical~~following ~~and~~exhibits ~~biotechnology industries~~ are ~~characterized~~filed byas ~~rapidly~~part ~~evolving~~of, ~~technology~~or ~~and~~incorporated ~~intense~~by ~~competition.~~reference ~~Our business development~~into, ~~clinical~~this ~~development,~~Quarterly ~~and~~Report ~~commercial~~on ~~efforts~~Form ~~may compete with more established companies that have significantly greater financial and managerial resources than we do~~10-Q.

We face competition from both very large, multi-national corporations with significant resources, and small start-up organizations. Our potential competitors include entities that develop and produce therapeutic agents. These include numerous public and private academic and research organizations and pharmaceutical and biotechnology companies pursuing production of, among other things, biologics from cell cultures, genetically engineered drugs and natural and chemically synthesized drugs. Our competitors may succeed in developing potential drugs or processes that are more effective or less costly than any that may be developed by us or that gain regulatory approval prior to our potential drug candidates. Many of these potential competitors have substantially greater capital resources, management expertise, research and development capabilities, manufacturing and marketing resources and experience than we do.

Exhibit No.		Document Description
31.1		Certification of the Principal Executive Officer Pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
31.2		Certification of the Principal Financial Officer Pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
32.1		Certification of the Principal Executive Officer pursuant to 18 U.S.C. 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
32.2		Certification of the Principal Financial Officer pursuant to 18 U.S.C. 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
101.INS		Inline XBRL Instance Document.*
101.SCH		Inline XBRL Taxonomy Extension Schema Document.*
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.*
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.*
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.*
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.*
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).*

~~Risks~~ __________ ~~Relating to Our Common Stock:~~

We* Filed ~~may have difficulty obtaining future funding sources, if needed, and we may have to accept terms that would adversely affect stockholders~~herewith.

We** Furnished ~~will need to raise funds from additional financing in the future to complete our business plan and may need to raise additional funding in the future to support our operations~~herewith. We have no commitments for any financing and any financing commitments may result in dilution to our existing stockholders. We may have difficulty obtaining additional funding and we may have to accept terms that would adversely affect our stockholders. For example, the terms of any future financings may impose restrictions on our right to declare dividends or on the way we conduct our business. Additionally, we may raise funding by issuing convertible notes, which if converted into shares of our common stock would dilute our then stockholders’ interests. Lending institutions or private investors may impose restrictions on a future decision by us to make capital expenditures, acquisitions, or significant asset sales. If we are unable to raise additional funds, we may be forced to curtail or even abandon our business plan.

~~Because~~19 weTable ~~are not subject to compliance with rules requiring the adoption~~ of ~~certain corporate governance measures, our stockholders have limited protections against interested director transactions, conflicts of interest and similar matters.~~Contents

The Sarbanes-Oxley Act of 2002, as well as rule changes proposed and enacted by the SEC, the New York Stock Exchange and the Nasdaq Stock Market, as a result of Sarbanes-Oxley, require the implementation of various measures relating to corporate governance. These measures are designed to enhance the integrity of corporate management and the securities markets and apply to securities that are listed on those exchanges or the Nasdaq Stock Market. Because we are not presently required to comply with many of the corporate governance provisions and because we chose to avoid incurring the substantial additional costs associated with such compliance any sooner than legally required, we have not yet adopted these measures.SIGNATURES

~~Because~~Pursuant weto ~~only have one Director, we do not currently have an independent audit or compensation committee. As a result, our Director has~~ the ~~ability~~requirements ~~to, among other things, determine her own level~~ of ~~compensation.~~the ~~Until~~Exchange ~~we comply with such corporate governance measures~~Act, ~~regardless of whether such compliance is required,~~ the ~~absence~~registrant ofhas ~~such~~duly ~~standards~~caused ofthis ~~corporate~~report ~~governance~~to ~~may~~be ~~leave~~signed ~~our~~on ~~stockholders~~its ~~without~~behalf ~~protections~~by ~~against~~the ~~interested director transactions~~undersigned, ~~conflicts~~thereunto ofduly ~~interest, if any, and similar matters and any potential investors may be reluctant to provide us with funds necessary to expand our operations~~authorized.

We intend to comply with all corporate governance measures relating to director independence as and when required. However, we may find it very difficult or be unable to attract and retain qualified officers, directors and members of board committees required to provide for our effective management as a result of the Sarbanes-Oxley Act of 2002. The enactment of the Sarbanes-Oxley Act of 2002 has resulted in a series of rules and regulations by the SEC that increase responsibilities and liabilities of directors and executive officers. The perceived increased personal risk associated with these recent changes may make it more costly or deter qualified individuals from accepting these roles.

	REGNUM CORP.

Date: May 23, 2022	By:	/s/ Anne Kirby
	Name:	Anne Kirby
	Title:	Chief Executive Officer
		(Principal Executive Officer)

	By:	/s/ Robert J. Stubblefield
	Name:	Robert J. Stubblefield
	Title:	Chief Financial Officer
		(Principal Accounting/Financial Officer)

We incur ongoing costs and expenses for SEC reporting and compliance and without sufficient revenues we may not be able to remain in compliance, making it difficult for investors to sell their shares, if at all.20

In order for us to remain in compliance with our on-going reporting requirements, we may require additional capital and/or future revenues to cover the cost of these filings, which could comprise a substantial portion of our available cash resources or require us to obtain additional capital through the sale of equity or debt. If we are unable to further capitalize the Company or generate sufficient revenues to remain in compliance, it may be difficult for you to resell any shares you may purchase, if at all. There are ongoing costs and expenses for SEC reporting, including the general bookkeeping and accounting costs for the preparation of the financial quarterly (Form 10-Qs) and annual filings (Form 10-Ks), and auditor’s fees. Further, there are processing costs in preparing and converting documents and disclosures through the EDGAR filing system, including certain costs for the XBRL that are required as part of the EDGAR filing. We estimate that these costs could result in up to $50,000 per year of ongoing costs.

19 Table of Contents

Stockholders may be diluted significantly through our efforts to obtain financing and satisfy obligations through the issuance of additional shares of our common stock.

We have no committed source of financing. Wherever possible, our Board of Directors will attempt to use non-cash consideration to satisfy obligations. In many instances, we believe that the non-cash consideration will consist of restricted shares of our common stock. Our Board of Directors has authority, without action or vote of the stockholders, to issue all or part of the authorized but unissued shares of common stock. In addition, if a trading market develops for our common stock, we may attempt to raise capital by selling shares of our common stock, possibly at a discount to market. These actions will result in dilution of the ownership interests of existing stockholders, may further dilute common stock book value, and that dilution may be material. Such issuances may also serve to enhance existing management’s ability to maintain control of the Company because the shares may be issued to parties or entities committed to supporting existing management.

Nevada law and our articles of incorporation authorize us to issue shares of stock, which shares may cause substantial dilution to our existing stockholders.

We have authorized capital stock consisting of 80,000,000 shares of common stock, $0.001 par value per share and 5,000,000 shares of preferred stock, $0.001 par value per share. As of the date of this Report, we have 22,950,000 shares of common stock issued and outstanding and no shares of preferred stock issued and outstanding. As a result, our Board of Directors has the ability to issue a large number of additional shares of common stock without stockholder approval, which if issued could cause substantial dilution to our then stockholders. The issuance of shares of common stock and/or preferred stock may cause the value of our securities to decrease and/or become worthless.

There is no material public market for our common stock.

Although our common stock is quoted on the OTC Pink Market maintained by OTC Markets, to date only a limited number of shares of our common stock have traded and a significant market may not develop in the future. If for any reason a public trading market does not develop, stockholders may have difficulty selling their common stock should they desire to do so.

Even if a more significant trading market develops, we cannot predict how liquid that market might become. The trading price of our common stock, if any, in the future, is likely to be highly volatile and could be subject to wide fluctuations in price in response to various factors, some of which are beyond our control. These factors include:

● Quarterly variations in our results of operations or those of our competitors; ● Announcements by us or our competitors;

● Disruption to our operations;

● Commencement of, or our involvement in, litigation;

● Any major change in our board or management;

● Changes in governmental regulations or in the status of our regulatory approvals; and

● General market conditions and other factors, including factors unrelated to our own operating performance.

20 Table of Contents

In addition, the stock market in general has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of such public companies. Such fluctuations may be even more pronounced in the future. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our actual operating performance. In addition, in the past, following periods of volatility in the overall market and the market price of a company’s securities, securities class action litigation has often been instituted against these companies. This type of litigation, if instituted against us, could result in substantial costs and a diversion of our management’s attention and resources.

There is currently a volatile, sporadic and illiquid market for our common stock.

Our securities are currently quoted on the OTC Pink Market maintained by OTC Markets under the symbol “RGMP,” however, we currently have a volatile, sporadic and illiquid market for our common stock, which is subject to wide fluctuations in response to several factors, including, but not limited to:

· actual or anticipated variations in our results of operations; · our ability or inability to generate new revenues; · increased competition; and · conditions and trends in the market for our services and products.

Furthermore, our stock price may be impacted by factors that are unrelated or disproportionate to our operating performance. These market fluctuations, as well as general economic, political and market conditions, such as recessions, global epidemics or pandemics, interest rates or international currency fluctuations may adversely affect the market price and liquidity of our common stock.

We have not paid any cash dividends in the past and have no plans to issue cash dividends in the future, which could cause the value of our common stock to have a lower value than other similar companies which do pay cash dividends.

We have not paid any cash dividends on our common stock to date and do not anticipate any cash dividends being paid to holders of our common stock in the foreseeable future. While our dividend policy will be based on the operating results and capital needs of the business, it is anticipated that any earnings will be retained to finance our future expansion. As we have no plans to issue cash dividends in the future, our common stock could be less desirable to other investors and as a result, the value of our common stock may decline, or fail to reach the valuations of other similarly situated companies who have historically paid cash dividends in the past.

Stockholders may face significant restrictions on the resale of our common stock due to federal regulations of penny stocks.

Our common stock will be subject to the requirements of Rule 15g-9, promulgated under the Exchange Act, as long as the price of our common stock is below $5.00 per share. Under such rule, broker-dealers who recommend low-priced securities to persons other than established customers and accredited investors must satisfy special sales practice requirements, including a requirement that they make an individualized written suitability determination for the purchaser and receive the purchaser’s consent prior to the transaction. The Securities Enforcement Remedies and Penny Stock Reform Act of 1990 also requires additional disclosure in connection with any trades involving a stock defined as a penny stock. Generally, the Commission defines a penny stock as any equity security not traded on an exchange or quoted on NASDAQ that has a market price of less than $5.00 per share. The required penny stock disclosures include the delivery, prior to any transaction, of a disclosure schedule explaining the penny stock market and the risks associated with it. Such requirements could severely limit the market liquidity of the securities and the ability of Company stockholders to sell their securities in the secondary market.

Sales of our common stock could reduce the price of our stock.

As of the date of this Report, we have 22,950,000 shares of our common stock which were registered under the Securities Act.

21 Table of Contents

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF THE PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This Quarterly Report on Form 10-Q (this “Report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this Report. These factors include:

● the need for additional funding; ● our lack of a significant operating history; ● the fact that our majority stockholder has significant control over our voting stock; ● the loss of key personnel or failure to attract, integrate and retain additional personnel; ● corporate governance risks; ● economic downturns; ● the level of competition in our industry and our ability to compete; ● our ability to respond to changes in our industry; ● our ability to protect our intellectual property and not infringe on others’ intellectual property; ● our ability to scale our business; ● our ability to maintain supplier relationships; ● our ability to obtain and retain customers; ● our ability to execute our business strategy in a very competitive environment; ● changes in laws and regulations; ● the market for our common stock; ● our ability to effectively manage our growth; ● dilution to existing stockholders; ● costs and expenses associated with being a public company; ● economic downturns both in the United States and globally; ● risk of increased regulation of our operations; and ● other risk factors included under “Risk Factors” below.

22 Table of Contents

You should read the matters described and incorporated by reference in “Risk Factors” and the other cautionary statements made in this Report, and incorporated by reference herein, as being applicable to all related forward-looking statements wherever they appear in this Report. We cannot assure you that the forward-looking statements in this Report will prove to be accurate and therefore prospective investors are encouraged not to place undue reliance on forward-looking statements. Other than as required by law, we undertake no obligation to update or revise these forward-looking statements, even though our situation may change in the future.

This information should be read in conjunction with the audited financial statements and the notes thereto included in this Quarterly Report on Form 10-Q.

In this Quarterly Report on Form 10-Q, we may rely on and refer to information regarding the industries in which we operate in general from market research reports, analyst reports and other publicly available information. Although we believe that this information is reliable, we cannot guarantee the accuracy and completeness of this information, and we have not independently verified any of it.

Unless the context requires otherwise, references to the “Company,” “we,” “us,” “our,” “Regnum”, and “Regnum Corp.” refer specifically to Regnum Corp.

In addition, unless the context otherwise requires and for the purposes of this Report only:

● “Exchange Act” refers to the Securities Exchange Act of 1934, as amended; ● “SEC” or the “Commission” refers to the United States Securities and Exchange Commission; and ● “Securities Act” refers to the Securities Act of 1933, as amended.

Where You Can Find Other Information

We file annual, quarterly, and current reports and other information with the SEC. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC like us at http://www.sec.gov. Copies of documents filed by us with the SEC are also available from us without charge, upon oral or written request to our Secretary, who can be contacted at the address and telephone number set forth on the cover page of this Report. The information on, or that may be accessed through, our website is not incorporated by reference into this Report and should not be considered a part of this Report.

Organizational History

Regnum Corp. was organized on March 31, 2016 under the laws of the State of Nevada. It was formed for the primary business purpose of servicing the increasing demand for premium entertainment content and becoming a depository of unpublished intellectual properties for resale with a focus on achieving profitability and sustaining business growth. Our business model was, until April 2021, based on acquiring unproduced and unpublished quality intellectual properties at a discount from studios, agencies, and production companies, for subsequent recycling or production in a wide variety of media, with the intent to resell such works back to the entertainment community for a profit. See “Recent Transactions and Changes of Control” below.

23 Table of Contents

Recent Transactions and Changes of Control

On April 7, 2021, Wookey, the previous majority shareholder of the Company, entered into a stock purchase agreement for the sale of 20,000,000 shares of Common Stock of the Company, to Phoenixus AG, an accredited investor. Phoenixus AG also acquired an additional 2,680,000 shares of common stock from three minority shareholders. In connection with the sale of such shares, an aggregate of 1,000,000 shares of common stock held by Gary Allen were returned to the Company for cancellation. As a result of the acquisition of 22,680,000 shares of common stock, and the cancellation of 1,000,000 shares, Phoenixus AG holds approximately 99% of the issued and outstanding shares of Common Stock of the Company, and as such it is able to unilaterally control the election of our board of directors, all matters upon which shareholder approval is required and, ultimately, the direction of the Company.

Also, on April 7, 2021, Mark Gustavson, former Chief Executive Officer, Secretary and Director of the Company, and Ross Meador, former Vice President and General Counsel of the Company, resigned their positions with the Company. Upon such resignations, Anne Kirby was appointed as Chief Executive Officer, President and sole Director. Rob Stubblefield remains the Chief Financial Officer of the Company.

Description of Business Operations:

Our prior business model was based on procuring unproduced and unpublished quality intellectual properties at a discount from independent writers, filmmakers, studios, agencies and production companies for subsequent reworking and/or production in a wide variety of media with intent to resell back to the entertainment community for profit.

As discussed herein, in April 2021, the prior business model was abandoned and the Company focus has shifted to developing and commercializing therapeutics that treat infectious diseases, specifically in rare populations or populations that face adherence challenges.

Management

The Company’s CEO is also its current sole director. Prior to these roles she was the Executive Vice President of an affiliated subsidiary which acted as the service provider to other affiliates and the affiliate that generated the largest revenue among the affiliated companies. She also acted as CEO of SevenScore. In addition to managing the Company generally and leading the management team and its related service providers, her ongoing efforts include, the development of marketing strategies and market access plans, establishing strategic partnerships with specialty pharmacies and patient services companies, and headcount planning. She will also take the lead in the Company’s efforts to in-license developmental and commercial stage products. While performing her role at the Company, she anticipates continuing to provide services pursuant to consulting and services agreements to Affiliates. Rob Stubblefield remains the Chief Financial Officer of the Company.

24 Table of Contents

Licensure and Regulation of Pharmaceutical and Biologic Products in the United States

In the United States, the FDA regulates human drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and in the case of biologic products, also under the Public Health Service Act, or the PHSA, and their implementing regulations. The failure to comply with the applicable U.S. requirements may result in FDA refusal to approve and may subject an applicant to administrative or judicial sanctions, such as issuance of warning letters, or the imposition of fines, civil penalties, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or civil or criminal prosecution brought by the FDA and the U.S. Department of Justice or other governmental entities.

The FDA must approve all products candidates for therapeutic indications before they may be marketed in the United States. An applicant seeking approval to market and distribute a new product in the United States generally must satisfactorily complete each of the following steps:

· completion of pre-clinical laboratory tests, animal studies and formulation studies according to good laboratory practices, or GLP, regulations or other applicable regulations; · submission to the FDA of an IND, which must become effective before human clinical trials may begin and must be updated when certain changes are made; · approval by an independent institutional review board, or IRB, or ethics committee representing each clinical trial site before each clinical trial may be initiated; · performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good clinical practices, or GCPs, and other clinical-trial related regulations to evaluate the safety and efficacy of the investigational product for each proposed indication; · preparation and submission to the FDA of the new drug application requesting marketing approval for one or more proposed indications, including payment of application user fees; · review of the application by an FDA advisory committee, where applicable; · satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the biologic is produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the product’s identity, strength, quality and purity; · satisfactory completion of any FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data submitted in support of the NDA/BLA; and · FDA review and approval of the application, which may be subject to additional post- approval requirements, including the potential requirement to implement a REMS, and any post- approval studies required by the FDA.

25 Table of Contents

Risks relating to the JOBS Act:

The JOBS Act allows us to postpone the date by which we must comply with certain laws and regulations and to reduce the amount of information provided in reports filed with the SEC. We cannot be certain if the reduced disclosure requirements applicable to “emerging growth companies” will make our common stock less attractive to investors.

We are and we will remain an “emerging growth company” until the earliest to occur of (i) the last day of the fiscal year during which our total annual revenues equal or exceed $1.07 billion (subject to adjustment for inflation), (ii) the last day of the fiscal year following the fifth anniversary of our initial public offering (which went effective on April 9, 2018), (iii) the date on which we have, during the previous three-year period, issued more than $1 billion in non-convertible debt securities, or (iv) the date on which we are deemed a “large accelerated filer” (with at least $700 million in public float) under the Exchange Act. For so long as we remain an “emerging growth company” as defined in the JOBS Act, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” as described in further detail in the risk factors below. We cannot predict if investors will find our common stock less attractive because we will rely on some or all of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We have availed ourselves of certain exemptions from various reporting requirements which are allowed pursuant to the JOBS Act and our reduced disclosure may make it more difficult for investors and securities analysts to evaluate us and may result in less investor confidence.

Our election not to opt out of JOBS Act extended accounting transition period may not make our financial statements easily comparable to other companies.

Pursuant to the JOBS Act, as an “emerging growth company”, we can elect to opt out of the extended transition period for any new or revised accounting standards that may be issued by the Public Company Accounting Oversight Board (PCAOB) or the SEC. We have elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an “emerging growth company”, can adopt the standard for the private company. This may make a comparison of our financial statements with any other public company which is not either an “emerging growth company” nor an “emerging growth company” which has opted out of using the extended transition period difficult or impossible as possible different or revised standards may be used.

The JOBS Act also allows us to postpone the date by which we must comply with certain laws and regulations intended to protect investors and to reduce the amount of information provided in reports filed with the SEC.

The JOBS Act is intended to reduce the regulatory burden on “emerging growth companies”. The Company meets the definition of an “emerging growth company” and so long as it qualifies as an “emerging growth company,” it will, among other things:

● be exempt from the provisions of Section 404(b) of the Sarbanes-Oxley Act requiring that its independent registered public accounting firm provide an attestation report on the effectiveness of its internal control over financial reporting;

● be exempt from the “say on pay” provisions (requiring a non-binding stockholder vote to approve compensation of certain executive officers) and the “say on golden parachute” provisions (requiring a non-binding stockholder vote to approve golden parachute arrangements for certain executive officers in connection with mergers and certain other business combinations) of The Dodd–Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank Act) and certain disclosure requirements of the Dodd-Frank Act relating to compensation of Chief Executive Officers;

26 Table of Contents

● be permitted to omit the detailed compensation discussion and analysis from proxy statements and reports filed under the Exchange Act and instead provide a reduced level of disclosure concerning executive compensation; and

● be exempt from any rules that may be adopted by the PCAOB requiring mandatory audit firm rotation or a supplement to the auditor’s report on the financial statements.

The Company intends to take advantage of all of the reduced regulatory and reporting requirements that will be available to it so long as it qualifies as an “emerging growth company”. The Company has elected not to opt out of the extension of time to comply with new or revised financial accounting standards available under Section 102(b)(1) of the JOBS Act. Among other things, this means that the Company’s independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of the Company’s internal control over financial reporting so long as it qualifies as an “emerging growth company”, which may increase the risk that weaknesses or deficiencies in the internal control over financial reporting go undetected. Likewise, so long as it qualifies as an “emerging growth company”, the Company may elect not to provide certain information, including certain financial information and certain information regarding compensation of executive officers, which it would otherwise have been required to provide in filings with the SEC, which may make it more difficult for investors and securities analysts to evaluate the Company. As a result, investor confidence in the Company and the market price of its common stock may be adversely affected.

Notwithstanding the above, we are also currently a “smaller reporting company”, meaning that we are not an investment company, an asset-backed issuer, or a majority-owned subsidiary of a parent company that is not a smaller reporting company and have a public float of less than $250 million and annual revenues of less than $100 million during the most recently completed fiscal year. In the event that we are still considered a “smaller reporting company”, at such time are we cease being an “emerging growth company”, the disclosure we will be required to provide in our SEC filings will increase, but will still be less than it would be if we were not considered either an “emerging growth company” or a “smaller reporting company”. Specifically, similar to “emerging growth companies”, “smaller reporting companies” are able to provide simplified executive compensation disclosures in their filings; are exempt from the provisions of Section 404(b) of the Sarbanes-Oxley Act requiring that independent registered public accounting firms provide an attestation report on the effectiveness of internal control over financial reporting; and have certain other decreased disclosure obligations in their SEC filings, including, among other things, only being required to provide two years of audited financial statements in annual reports. Decreased disclosures in our SEC filings due to our status as an “emerging growth company” or “smaller reporting company” may make it harder for investors to analyze the Company’s results of operations and financial prospects.

27 Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	REGNUM CORP.
Date: November 22, 2021	By:	/s/ Anne Kirby
		Anne Kirby
		Chief Executive Officer
		(Principal Executive Officer)
Date: November 22, 2021	By:	/s/ Robert J. Stubblefield
		Robert J. Stubblefield
		Chief Financial Officer
		(Principal Accounting/Financial Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By:	/s/ Anne Kirby	By:	/s/ Robert J. Stubblefield
	Anne KirbyChief Executive Officer(Principal Executive Officer)and Director		Robert J. StubblefieldChief Financial Officer(Principal Accounting/Financial Officer)
Date:	November 22, 2021	Date:	November 22, 2021

28 Table of Contents

ITEM 6. EXHIBITS

EXHIBIT INDEX

Exhibit No.		Document Description
3.1		Articles of Incorporation of Regnum Corp. (1)
3.2		Bylaws of Regnum Corp. (1)
2.1		Agreement and Plan of Merger Agreement, dated May 13, 2021, by and among Regnum Corp., and SevenScore Pharmaceuticals LLC. (incorporated by reference to Exhibit 2.1 to the Form 8-K, filed May 20, 2021)
2.2		Management Agreement, effective as of April 7, 2021, by and among Regnum Corp., and SevenScore Pharmaceuticals LLC. (incorporated by reference to Exhibit 2.1 to the Form 8-K, filed April 9, 2021)
2.3		Form of Consulting Agreement, effective as of April 7, 2021, by and among Regnum Corp., and Robert Stubblefield. (incorporated by reference to Exhibit 2.2 to the Form 8-K, filed April 9, 2021)
21.1*		Subsidiaries of the Registrant
31.1*		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**		Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002
32.2**		Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002

Filing Compare · Regnum Corp.